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 INTRODUCTION
A drug1 may be defined as substance meant for diagnosis, cure, mitigation, prevention
and treatment of disease in human beings or animals, for altering any structure or function of
the body of human beings or animals2. Pharmaceutical chemistry3-6 is a science that makes
use  of  general  laws  of  chemistry  to  study  drugs  i.e.  their  preparation,  chemical  nature,
composition,  structure,  influence on an organism, the methods of  quality control  and the
conditions of their storage etc. The family of drugs may be broadly classified as
1. Pharmacodynamic agents
2. Chemotherapeutic agents
Pharmacodynamic  agents7 refer  to  a  group  of  drugs  which  stimulates  or  depress
various  functions  of  the  body so as  to  provide some relief  to  the  body in case  of  body
abnormalities without curing the disease.
Chemotherapeutics agents are drugs, which are selectively more toxic to the invading
organisms  without  causing  harmful  effect  to  the  host.  E.g.  Antimalarial,  antibacterial,
antifungal agents
Every country has legislations8 on bulk drug and their pharmaceutical formulations
that sets standards and obligatory quality indices for them. These regulations are presented in
separate articles relating to individual drugs and are published in the form of book called
“Pharmacopoeia” [e.g. IP9, BP10 and Martindale Extra Pharmacopoeia11 (MEP)]
Pharmaceutical  Analysis12-15 plays  a  very  significant  role  in  quality16 control  of
pharmaceuticals  through  a  rigid  check  on  raw  materials  used  in  manufacturing  of
formulations  and on finished products.  It  also plays  an important  role in building up the
quality products through in process quality control. Pharmaceutical analysis is the application
of principles of analytical chemistry to drug analysis. The analytical chemistry17-20 may be
defined as the science of developing sensitive, relative and accurate methods for determining
the composition of materials in terms of elements or compounds which they contain. These
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analytical  results  have  played  critical  roles  from the  understanding of  basic  science  to  a
variety of practical applications such as biomedical applications, environmental monitoring,
quality control of industrial manufacturing and forensic science.
The  methods  of  estimation  of  drugs  are  divided  into  physical,  chemical,
physicochemical and biological ones. Physico-chemical and physical methods are used the
most.  Physical  methods  of  analysis  involve  the  study  of  the  physical  properties  of  a
substance.  They  include  determination  of  solubility,  transparency  or  degree  of  turbidity,
colour density, specific gravity (for liquids), moisture content, melting, freezing and boiling
points. Physicochemical methods21-23 are used to study the physical phenomenon that occurs
as result of chemical reactions. Among the physicochemical methods, the most important are
optical  (refractometry,  polarimetry  including  photocolourimetry  and  spectrophotometry
covering  UV-visible  and  IR  regions  nephelometry  or  turbidimetry)  and  chromatographic
(column, paper, thin-layer24, gas liquid25-26, HPLC27-28) methods. The number of new drugs is
constantly growing. This requires new methods for controlling the quality.
Types of analytical chemistry29-30
Traditionally, analytical chemistry has been split into two main types, qualitative and
quantitative:
 There are main two types of chemical analysis. 
              1. Qualitative (identification) 
2. Quantitative (estimation)
1. Qualitative analysis is performed to establish composition of natural/synthetic substances.
These tests are performed to indicate whether the substance or compound is present in the
sample or not. Various qualitative tests are detection of evolved gas, formation of precipitates,
limit tests, colour change reactions, melting point and boiling point test etc.
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2.  Quantitative  analytical techniques  are  mainly  used  to  quantify  any  compound  or
substance in the sample. These techniques are based on
(a)  The quantitative  performance  of  suitable chemical  reaction  and  either  measuring  the
amount  of  reagent  added  to  complete  the  reaction  or  measuring  the  amount  of  reaction
product obtained 
(b) The characteristics movement of a substance through a defined medium under   controlled
conditions 
(c)  Electrical measurement
 (d) Measurement of some spectroscopic properties of the compound.  
Different techniques of Analysis
1. Methods based on chemical analysis 31-33
These methods are based on traditional method of analysis and may be divided as:
(i) Titrimetric
(ii) Gravimetric
(iii) Volumetry
i. Titrimetric Analysis34
In  this  technique  the  substance  to  be  determined  is  allowed  to  react  with  an
appropriate  reagent  added  as  a  standard  solution  and  the  volume of  solution  needed  for
completion on reaction is determined. Following are the types of titrimetric analysis:
• Neutralization (acid-base) reactions. 
• Complexometric titrations
• Precipitation titrations 
• Oxidation- reduction titrations
• Non aqueous titrations
ii. Gravimetric Analysis35:
In  this  technique  substance  under  determination  is  converted  into  an  insoluble
precipitate  which  is  collected  and  weighed.  In  a  special  case  of  gravimetric  analysis,
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electrolysis of the substance is carried out and the material deposited on one of the electrodes
is weighed. This technique is called as electrogravimetry.
iii. Volumetry Analysis:
It is concerned with measuring the volume of gas evolved or absorbed in a chemical
reaction.
2. Electrical Methods of Analysis36-37: These involve the measurement of current voltage or
resistance in relation to the concentration of a certain species in a solution. These methods are
of following types: 
a) Voltametry: 
         It is the measurement of current at a microelectrode at a specified voltage. 
b) Coulometry: 
         It  is the measurement of current and time needed to complete an electrochemical
reaction or to generate sufficient material to react completely with a specified reagent. 
c) Conductometry:
It is the measurement of electrical conductivity of a solution. The ionic reactions in
which there is a sudden change in conductance after completion of reaction, can act as a basis
of conductometric titration method. 
d) Potentiometry:
It is the measurement of the potential of an electrode in equilibrium with an ion to be
determined.
3. Optical methods of analysis38-40
The optical methods are basically of two types: 
i. Absorption methods 
ii. Emission methods. 
i. Absorption methods:
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Absorption  spectroscopy refers  to  spectroscopic techniques  that  measure  the
absorption of radiation, as a function of frequency or wavelength, due to its interaction with a
sample. The sample absorbs energy, i.e., photons, from the radiating field. The intensity of
the absorption varies as a function of frequency and this variation is the absorption spectrum.
Absorption  spectroscopy  is  performed  across  the  electromagnetic  spectrum.  Absorption
spectroscopy is  employed  as  an  analytical  chemistry tool  to determine the presence of  a
particular substance in a sample and in many cases, to quantify the amount of the substance
present. 
Absorption methods are usually classified according to wavelength involved: 
i. Visible spectrophotometry 
ii. Ultraviolet spectrophotometry 
iii. Infrared spectrophotometry 
Visible spectrophotometry:
The method of analysis is based on measuring the absorption of monochromatic light
by colored compounds in the visible path of the spectrum (370-800 nm). If the analytes are
colorless,  they  are  converted  into  colored  compounds  by  reaction  with  a  suitable
chromogenic  reagent.  In  this  case,  the majority of  colored  compounds are complexes  or
complex ligands. The later must be stable and have a constant composition and high color
intensity. The photometric methods of analysis are based on the Bouger-Lambert-Beer’s law,
which establishes that absorbance by a solution is directly proportional to the concentration
of the analyte. The fundamental principle of operation of spectrophotometer covering visible
region consists  in that  light  of  definite  interval  of wavelength passes  through the radiant
energy into electrical energy measured by galvanometer.
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The absorption of light by analytes is due to the presence of chromophores in their
molecules, which are specific portions of molecules can absorb radiant energy in the UV or
visible  region.  They  include  unsaturated  functional  groups.  Every  functional  group  in  a
molecule of a substance is characterized by the absorption of light in a definite region of the
spectrum and this property is used for the identification and quantification of a substance in a
drug. In addition to chromophores, a molecule may contain one or more saturated functional
groups that themselves do not absorb in the UV/visible region being scanned, but can affect
the  behaviour  of  the  chromophores  that  are  conjugated  with  these  groups  are  called
auxochrome (e.g.  SH,  NO2, OH),  which  usually  cause  absorption  by a  chromophores  at
higher  wavelength  and  at  a  longer  value  of  the  absorptivity  than  found  for  the  given
chromophores itself.
Absorption spectrum
The absorption spectrum is a graphical representation of the amount of light absorbed
by a substance at definite wavelengths. To plot absorption curve, the value of the wavelength
(λ) are laid off along the axis of abscissas and the values of the absorbance along the axis of
the ordinates. A characteristic of an absorption spectrum is a position of the peaks (maxima)
of light absorption, which is determined by the absorptivity at definite wavelengths. 
Beer’s law plot
A standard  specimen  of  the  analyte  is  taken  and  the  solutions  of  it  with  known
concentrations are prepared. The absorbance of all the solutions are measured at a definite
wavelength (λmax) and the calibration curve is plotted by laying off the known concentrations
along the axis abscissas and the absorbances corresponding to them along the axis ordinates.
The calibration curve is used to determine the unknown concentration of the analyte in its
solutions.
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A feature of organic drugs is the presence of functional groups in their molecules i.e.,
reactive  atoms  or  groups  of  atoms determined  by chemical  reactions.  Functional  groups
determine the way of analysing organic drugs because they are responsible for the properties
of  substance  and  determine  the  identification  reactions  and  the  methods  of  quantitative
determination of drugs. Knowing the reactions for detecting functional groups, one can easily
and conscientiously analyze any organic drug with a complicated structure. There are several
drug molecules, which are poly functional in nature, i.e., simultaneously contain two or more
functional groups41-44.
ii. Emission Method
In  emission method sample is subjected to heat or electrical treatment so that the atoms
are raised to excited states causing them to emit-energy; and the intensity of this emitted
energy is measured. The emission spectroscopy includes flame photometry and fluorimetry.
In emission spectroscopy the sample is subjected to flame, electric arc or spark plasma and
the light emitted is examined. Flame photometry involves the solution of the sample, injected
into a flame while in fluorimetry a suitable substance in solution is excited by irradiating with
visible or ultraviolet radiation. 
Chromatography45-48
Introduction:
Chromatography (from Greek: chroma, colour and: grafein to write) is the collective
term for a family of laboratory techniques for the separation of mixtures. It involves passing a
mixture dissolved in a "mobile phase" through a stationary phase, which separates the analyte
to be measured from other molecules in the mixture and allows it to be isolated.
Chromatography may be preparative or analytical. Preparative chromatography seeks
to separate the components of a mixture for further use (and is thus a form of purification).
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Analytical chromatography normally operates with smaller amounts of material and seeks to
measure the relative proportions of analytes in a mixture. The two are not mutually exclusive.
Types of Chromatography49-51
Chromatography can be divided into three subsections namely gas,  gel  and liquid
chromatography.  Gas  chromatography  is  used  for  the  analysis  of  volatile  samples,  gel
chromatography for non-volatile samples with a molecular weight smaller than 2000.
Gas Chromatography (GC) 52-54
Gas  chromatography  is  a chromatographic technique  that  can  be  used
to separate organic compounds that are volatile. A gas chromatography consists of a flowing
mobile  phase,  an  injection  port,  a  separation  column  containing  the  stationary  phase,  a
detector,  and  a  data  recording  system.  The  organic  compounds  are  separated  due  to
differences in their partitioning behaviour between the mobile gas phase and the stationary
phase in the column.
High-performance liquid chromatography (HPLC) 55-56
In the field of analytical chemistry high performance liquid chromatography (HPLC)
is considered by many to be most exciting and dynamic technique of past decade. The typical
HPLC separation is based on the selective distribution of analytes between a liquid mobile
phase and an immiscible stationary phase. The sample is first introduced by means of an
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injection port into the mobile phase stream that is delivered by a high-pressure pump. Next,
the components of this sample mixture are separated on the column, a process monitored with
a flow-through detector as the isolated components emerge from the column.
General Methodology for Analytical Method Development
Development of a method57-58:
In developing a quantitative method for determining an unknown concentration of a
given  substance  by absorption  spectrophotometry,  the  first  step  will  be  the  selection  of
analytical wavelength which can be chosen either from literature or experimentally by means
of a scanning spectrum in the UV-Visible region. In order to enhance the sensitivity of the
method  and  signal  to  noise  ratio,  the  wavelength  of  maximum absorbance  is  chosen  as
analytical wavelength.
After selection of the wavelength, the colour developing reagent and the absorbing
product must be stable for a considerable period of time. Always the preparation of standards
and unknown should be on a definite time schedule. 
Optimization of analytical method59:
The bases of the spectrophotometric methods, in the present investigation are
(a) Oxidative coupling
(b) Oxidation followed by complex formation 
(c) Diazotization and coupling  
(d) Complex formation. 
In  each  type  of  reaction,  the  yield  of  the  coloured  species  whose  absorbance  is
measured and thus the sensitivity of the method, rate of color formation and stability are
affected by the concentration of the reagent in the solution. The nature of the solvent, the
temperature, the pH of the medium, order of addition of reactants and waiting periods also
affect the above parameters. For simple systems having no interaction between variables, the
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one variable at time (OVAT) strategy appears to be simple, efficient and effective to establish
the optimum conditions. The OVAT approach requires all variable but one to be held constant
while a univariate search is carried out on the variable of interest. 
Calibration:
Calibration is one of the most important steps in drug analysis. A good precision and
accuracy  can  only  be  obtained  when  good  calibration  procedure  is  used.  In
spectrophotometric methods the concentration of a sample cannot be measured directly, but is
determined using another physical measuring quantity, “Y” (absorbance of a solution). An
unambiguous empirical or theoretical relationship can be shown between this quantity and
concentration of the analyte.
For the majority of analytical techniques the analyst uses the calibration equation.
                                                          Y= a + bX
In  calibration,  univariate  regression  is  applied,  which  means  that  all  observations  are
dependent upon a single variable “X”.
The method of least squares60:
Least squares regression analysis is used to describe the relationship between signal
and  concentration.  All  models  describe  the  relationship  between  response  (Y)  and
concentration (X) can be represented by general function.
                   Y= f(X, a1, b1............bm)
 Where a1, b1............bm are the parameters of the function
      We adopt the convention that  ‘X’ values relate  to the controlled or independent
variable and the ‘Y’ values to the dependent variable. This means that ‘X’ value has no error.
On the condition that errors made in preparing the standards are significantly smaller than the
measuring errors this assumption is  realistic in calibration problems.       The values of
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unknown parameter a1, b1............bm  must be estimated in such a way that the model fits the
experimental data points as far as possible.
The true relationship between X and Y is considered to be given by a straight line. The
relationship between each observation pair (Xi, Yi) can be represented as 
                                         Yi=α + βXi + ei
The signal Yi is composed of a deterministic component predicted by linear model and a
random component ei. One must now find the estimates ‘a’ and ‘b’ of the true values and α
and β which are constants. This is done by calculating values ‘a’ and ‘b’ for which  ∑ei2  is
minimal. The component ei represents the difference between the observed Yi values by the
model.
 
The ei are called the residuals, ‘a’ and ‘b’ are the intercept and slope respectively. The
equation given for slope and intercept of the line are as follows.
           
                                              n∑iXi Yi -∑iXi . ∑iYi  
                   Slope (b) =           
                                            n∑iXi2 – [∑iXi]2
                                       ∑iYi∑iXi2-∑iXi . ∑iXi Yi
         Intercept (a) =
                                      n∑iXi2 – [∑iXi]2   
 Correlation coefficient (r)
The correlation coefficient r (x, y) is more useful to express the relationship of the chosen
scales.  To  obtain a  correlation,  the covariance  is  divided  by the  product  of  the  standard
deviation of x and y.
r=
[∑
i=1
n
(X iX )(Y iY )]
(n1 )
[∑
i=1
n
(X iX )
2∑
i=1
n
(Y iY )
2]
(n1 )2
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Where   X ,Y  are the arithmetic means of X and Y respectively.
Selectivity of the method
        The determination of an analyte may be disturbed by matrix and interference effect.
Some of the excipients, incipient and additives present in pharmaceutical formulations may
sometimes interfere in the assay of the drug and in such instances appropriate separation
procedure is to be adopted initially. The selectivity of the method ascertained by studying the
effect of a wide range of excipients and other additives usually present in the pharmaceutical
formulation on the determinations under optimum conditions.
              In the initial interference studies, a fixed concentration of the drug is determined
several times by the optimum procedure in the presence of suitable (1 to 100 fold) molar
excess of foreign compounds under investigation and its effect on absorbance of solution is
noticed. The foreign compound is considered to be non-interfering if at these concentrations,
it constantly produces an error less than 3% in the absorbance produced in the pure sample
solution.
Linearity and sensitivity of the method
              Knowledge of the sensitivity of the color is important and the following terms are
commonly employed for expressing the sensitivity. According to the Beer’s law
                            
          Intensity of incident radiation
                A= log                                                 =   ε.C.T
                              Intensity of transmitted light
The absorbance (A) is proportional to the concentration (C) of absorbing species if
absorptivity (ε) and thickness of the medium (t) are constant. When ‘C’ is in moles per liter,
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the constant ε is called the molar absorptivity. Beer’s law and εmax  values are expressed as
μg/ml and mole-1cm -1 respectively.
Sandell’s sensitivity61 refers to the number of μg of the drug determined, converted to
the colored product, which in a column solution of cross section 1cm2  shows an absorbance
0.001 (expressed as μg cm-2) 
Ringbom’s plot62
The relative concentration error depends inversely upon the product absorbance and
transmittance. The relative error increases at the extremes of the transmittance (T) scale. The
slope of plot ‘C’ versus T, i.e. Ringbom’s plot gives relative coefficient (i.e. plot of log C α
T). The main limitation of the ringbom’s  plot is that it provides no information concerning
the concentration range of good precision unless it is combined with ∆T versus T relation.
The above expression is valid whether or not Beer’s law is valid.
Recovery experiments (standard addition method)
A known amount of the constituent being determined is added to the sample which is
analyzed for the total amount of constituent present. The difference between the analytical
results for samples with and without the added constituent gives the recovery of the amount
of  added  constituent.  If  recovery  is  satisfactory  our  confidence  in  the  accuracy  of  the
procedure will be enhanced. 
Usually,  recovery  studies  are  performed  while  proceeding  for  pharmaceutical
formulations;  known  amounts  of  an  analyte  are  spiked  at  different  levels  into  a  sample
matrix, which was already analyzed. The concentration of the analyte in the original sample
may then be determined mathematically.
                % Recovery = [N (∑ XY )∑ X .∑YN (∑ X 2)(∑ X )2 ]×100
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X= amount of standard drug
Y= amount of drug found by the proposed method
N= Number of observations
ANALYTICAL METHOD VALIDATION AS PER ICH GUIDELINES63-66
Method validation is the process to confirm that the analytical procedure employed
for a specific test is suitable for its intended use. Methods need to be validated or revalidated.
• Before their introduction into routine use.
• Whenever the conditions change for which the method has been validated,
e.g., instrument with different characteristics.
• Whenever  the  method is  changed,  and the  change  is  outside  the  original
scope of the method.
Method validation is completed to ensure that an analytical methodology is accurate,
specific, reproducible and rugged over the specified range that an analyte will be analyzed.
Method validation provides an assurance of reliability during normal use, and is sometime
referred to as "the process of providing documented evidence that the method does what it is
intended to do." Regulated laboratories must perform method validation in order to be in
compliance with FDA regulations.
For method validation, these specifications are listed in USP Chapter <1225>, and can
be referred to  as the "Eight  Steps  of  Method Validation".  These terms are referred to  as
"analytical performance parameters", or sometimes as "analytical figures of merit." 
In response to this situation, one of the first harmonization projects taken up by the
ICH  was  the  development  of  a  guideline  on  the  "Validation  of  Analytical  Methods:
Definitions and Terminology67." 
METHOD VALIDATION
The developed methods were validated by following steps
        • Accuracy
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        • Precision
        • Specificity
        • Limit of quantitation
        • Limit of detection
        • Linearity and range
        • Ruggedness and
        • Robustness
Accuracy:
It  is  defined as closeness of  agreement  between the actual  (true)  value and mean
analytical  value  obtained  by  applying  a  test  method  number  of  times.  Accuracy  of  an
analytical method is determined by systematic error involved. The accuracy is acceptable if
the difference between the true value and mean measured value does not exceed the RSD
values obtained for repeatability of the method.
The parameter provides information about the recovery of the drug from sample and
effect of matrix, as recoveries are likely to be excessive as well as deficient. 
To document accuracy,  the ICH guideline on methodology recommends collecting
data from a minimum of nine determinations over a minimum of three concentration levels,
covering the specified range (for example, three concentrations, three replicates each).
Accuracy is calculating the percentage recovery by the assay of the known amount of
analyte in the sample or as the difference between the mean and the accepted true value,
together with confidence intervals.
For assay method, spiked samples are prepared in triplicate at three intervals over a
range of 50-100% of the target concentration. Potential impurities should be added to the
matrix  to  mimic  impure  samples.  The  analyte  levels  in  the  spiked  samples  should  be
determined  using  the  same  quantitation  procedure  as  will  be  used  in  the  final  method
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procedure  (i.e.  same  levels  of  standards  and  same  number  of  samples  and  standard
injections).           
Precision:
The precision of an analytical method is the degree of agreement among individual
test  results  when  the  method is  applied  repeatedly to  multiple  sampling  of  homogenous
sample. Precision is the measure of the degree of repeatability of an analytical method under
normal operation and is normally expressed as the percent relative standard deviation for a
statistically  significant  number  of  samples.  According  to  the  ICH,  precision  should  be
performed at three different levels: repeatability, intermediate precision, and reproducibility.  
The precision of an analytical method is determined by assaying a sufficient number
of aliquots of a homogenous sample to be able to calculate statistically valid estimates of
standard deviation or relative standard deviation. The ICH documents recommended that the
repeatability  should  be  assessed  using  a  minimum  of  nine  determinations  covering  the
procedure  (i.e.  three  concentration  and  three  replicates  of  each  concentrations  using  a
minimum of six determinations at 100% of the test concentrations)
In the case of instrument precision, six replicates of the standard solution are made for
the test performance of the chromatographic instrument.
In the case of  method precision, six replicates from the same batch are analyzed for
the assay and dissolution parameters and observing the amount of scatter in the results. An
example of precision criteria of an assay method is that the instrument precision RSD should
not be more than 2.0%.
Repeatability is the results of the method operating over a short time interval under
the same conditions (inter-assay precision). It should be determined from a minimum of nine
determinations covering the specified range of the procedure (for example, three levels, three
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repetitions each) or  from a minimum of six  determinations at  100% of the test  or  target
concentration.
Intermediate precision is the results from within lab variations due to random events
such  as  different  days,  analysts,  equipment,  etc.  In  determining  intermediate  precision,
experimental design should be employed so that the effects (if any) of the individual variables
can be monitored.
Reproducibility  refers to the results of collaborative studies between laboratories.
Documentation in support of precision studies should include the standard deviation, relative
standard deviation, coefficient of variation, and the confidence interval.
Specificity:
It is the ability of an analytical method to assess unequivocally the analyte of interest
in  the  presence  of  components  that  may be  expected  to  be  present,  such  as  impurities,
degradation  products  and  matrix  components.  In  case  of  the  assay,  demonstration  of
specificity  requires  that  the  procedure  is  unaffected  by  the  presence  of  impurities  or
excipients.  In  practice,  this  can be done by spiking the drug substances  or  product  with
appropriate levels of impurities or excipients and demonstrating that the assay is unaffected
by the presence of these extraneous materials. If the degradation product impurity standards
are unavailable, specificity may be demonstrated by comparing the test results of samples
containing  impurities  or  degradation  products  to  a  second  well-characterized  procedure.
These comparisons should include samples stored under relevant stress conditions (e.g. light,
heat humidity, acid/base hydrolysis, oxidation, etc.).
Limit of Detection:
The limit of detection (LOD) is defined as the lowest concentration of an analyte in a
sample that can be detected, not quantitated. It is a limit test that specifies whether or not an
analyte is above or below a certain value. It  is expressed as a concentration at a specified
signal-to-noise ratio, usually two or three-to-one. The ICH has recognized the signal-to-noise
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ratio convention, but also lists two other options to determine LOD: visual non-instrumental
methods and a means of calculating the LOD. Visual non-instrumental methods may include
LOD’s  determined  by techniques  such  as  thin  layer  chromatography (TLC)  or  titrations.
LOD’s may also be calculated based on the standard deviation of the response (SD) and the
slope of the calibration curve (S) at levels approximating the LOD according to the formula:
LOD = 3.3(SD/S). The standard deviation of the response can be determined based on the
standard deviation of the blank, on the residual standard deviation of the regression line, or
the standard deviation of y-intercepts of regression lines. The method used to determine LOD
should  be  documented  and  supported  and  an  appropriate  number  of  samples  should  be
analyzed at the limit to validate the level.
Limit of Quantitation:
The Limit of Quantitation (LOQ) is defined as the lowest concentration of an analyte
in a sample that can be determined with acceptable precision and accuracy under the stated
operational conditions of the method. Like LOD, LOQ is expressed as a concentration, with
the precision and accuracy of the measurement also reported. Sometimes a signal-to-noise
ratio of ten-to-one is used to determine LOQ. This signal-to-noise ratio is a good rule of
thumb, but it should be remembered that the determination of LOQ is a compromise between
the concentration and the required precision and accuracy. That is, as the LOQ concentration
level decreases, the precision increases. If better precision is required, a higher concentration
must be reported for LOQ. This compromise is dictated by the analytical method and its
intended use. The ICH has recognized the ten-to-one signal-to-noise ratio as typical, and also,
like LOD, lists the same two additional options that can be used to determine LOQ, visual
non-instrumental methods and a means of calculating the LOQ. The calculation method is
again based on the standard deviation of the response (SD) and the slope of the calibration
curve (S) according to the formula: LOQ = 10(SD/S). 
Linearity and Range:
18
Linearity is the ability of the method to elicit test results that are directly proportional
to analyte concentration within a given range. Linearity is generally reported as the variance
of the slope of the regression line. Range is the interval between the upper and lower levels of
analyte (inclusive) that have been demonstrated to be determined with precision, accuracy
and linearity using the method as written. The range is normally expressed in the same units
as the test results obtained by the method ICH25 recommended that, for the establishment of
linearity,  a  minimum  of  five  concentrations.  It  is  also  recommended  that  the  following
minimum specified range should be considered. For assay of a drug substance or a finished
product  80-120%  of  the  test  concentration  should  be  taken. For  an  impurity  test,  the
minimum range is from the reporting level of each impurity, to 120% of the specification.
(For toxic or more potent impurities, the range should be commensurate with the controlled
level.)         
Acceptability of the linearity data is often judged by examining the correlation co-
efficient and y-intercept of the linear regression line for the response versus concentration
plot. The correlation coefficient of >0.999 is generally considered as evidence of acceptable
fit of the data to the regression line. The y-intercept should be less than a few percent of the
response obtained for the analyte at to target level.
Ruggedness:
Ruggedness,  according to  the  USP,  is  the  degree  of  reproducibility  of  the  results
obtained under a variety of conditions, expressed as %RSD. The ruggedness of an analytical
method is the degree of reproducibility of test results obtained by the analysis of the same
samples  under  a  variety  of  conditions  such  as  different  laboratories,  different  analysts,
different instruments, different lots of reagents, different elapsed assay times, different assay
temperatures, different days, etc.
Robustness:
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Robustness  is  the  capacity  of  a  method to  remain  unaffected  by small  deliberate
variations in method parameters. The robustness of a method is evaluated by varying method
parameters such as percent organic, pH, ionic strength, temperature, etc., and determining the
effect (if any) on the results of the method. As documented in the ICH guidelines, robustness
should be considered early in the development of a method. In addition, if the results of a
method or  other  measurements  are  susceptible  to  variations  in  method parameters,  these
parameters should be adequately controlled and a precautionary statement included in the
method documentation.
The  robustness  of  the  methods  was  determined  by  performing  the  assay  of  the
triplicate by deliberately alternating parameters and that the results  are not influenced by
different changes in the above parameters
   Change in column temperature ±50C
   Change in flow rate ±10%.
   Change in organic phase ± 2%.
   Change in pH ± 0.2.
The system suitability and the precision of the assay were evaluated for the respective
condition. The robustness of an analytical procedure is the measure of its capability to remain
unaffected  by  small,  but  deliberate,  variation  in  method  parameters  and  providers  an
indication of its reliability during normal usage.
Chromogenic reagents used in the present investigation.
Functional  groups  present  in  organic  drugs  determine  the  way of  analyzing them
because they are responsible for the properties of substances and determine the identification
reaction and the methods of quantitative determination of drugs. Knowing the reactions for
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detecting functional  groups,  one can easily analyze  any organic drug with a  complicated
structure.  In  the present  investigation,  few visible spectrophotometric  methods have been
developed for Pregabalin and Zolpidem by developing colour in each case with, appropriate
reagent.  The  analytically  useful  functional  groups  in  the  drug  have  not  been  exploited
completely in developing the new visible spectrophotometric method and so, the drugs have
been selected in the present investigation.
Different  type  of  reagents  like  Folin’s,  Sanger’s,  Brady’s,  Para  chloranilic  acid,
Gibb’s,  MBTH, BM reagent were used in the present investigation for developing visible
spectrophotometric methods.
1, 2- Napthoquinone-4-sulphonate (NQS reagent) 68-69
NQS reagent is also called as Folin’s reagent. This reagent reacts with the compounds
containing amine group. In the present study due to the presence of amine as chromophoric
group in the Pregabalin molecule, derivatization of the compound was attempted with this
reagent,  as  a  result  colored  complex  has  been  formed  which  was  estimated
spectrophotometrically. This reagent was generally prepared in water.
1-Flouro-2, 4-dinitrobenzene70-71
1-Flouro-2,  4-dinitrobenzene  is  also  called  as Sanger’s  reagent.  Sanger’s  reagent
reacts with the compounds containing amine group. The reaction of pregabalin with Sanger’s
reagent  resulted in  the formation of  Zwitter-ion-like structure due to  the presence of  the
carboxylic acid group adjacent to amino group. Reagent was prepared in methanol for the
present study. Reagent was highly skin irritant and stable up to seven days if stored in the
refrigerator. Care must be taken while using it.
2, 4-Dinitrophenyl hydrazine72-73
2,  4-Dinitrophenyl  hydrazine  reagent  is  also  called  as  Brady’s  reagent.
Dinitrophenylhydrazine is relatively sensitive to shock and friction; it is a shock explosive so
21
care must be taken with its use. It is red to orange solid, usually supplied wet to reduce its
explosive  hazard.  It  is  a  substituted hydrazine,  and  is  often  used  for  the
determination carbonyl  groups associated  with  aldehydes and ketones.  The  reagent  was
generally prepared in water.
Parachloranilic acid74-75
p-Chloranilic acid mainly involves in the charge transfer reactions. P-CA acts as a pi
acceptor.  The interaction of drug with pi-acceptor (p-CA) at room temperature was found to
yield colored charge transfer complex. In polar solvents, complete electron transfer from drug
as an electron donor, to the acceptor moiety takes place resulting in the formation of intensely
colored radical anions. The reagent was prepared in methanol for the present investigation.
2, 6 Dichloroquinone chlorimide76-77
2,  6  Dichloroquinone  chlorimide  is  also  called  as  Gibb’s  reagent.  Gibb’s  reagent
mainly reacts with  phenols,  primary amines,  secondary amines,  aliphatic amines.  For the
present study the reagent was prepared in methanol.
3-Methyl 2-benzathiozolinone hydrazone78-80
MBTH is synthesized by Besthron.  MBTH can react with carbonyl compounds and
compounds containing amine group. It  also forms a strongly electrophillic diazonium salt
when acted upon by an oxidizing agent. Ferric chloride has been mostly used as the oxidizing
agent for the determination of amines. For the present study the reagent was prepared in
distilled water.
Bratton Marshal reagent (BMR) 81-82
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Bratton  Marshal  reagent  is  also  called  as  N-(1-naphthyl)  ethylene  diamine
dihydrochloride. It was white to light tan or grey crystalline solid or off white powder. It was
prepared by dissolving in water. It was light sensitive and hygroscopic. It mainly reacts with
the compounds containing amine as the functional group. 
Central nervous system (CNS) acting drugs are widely used to treat various diseases
like  Parkinsonism,  Schizophrenia,  Mania,  Epilepsy,  Insomnia,  Depression,  Anxiety,
Meningitis  etc.  A  number  of  novel  drugs  like  Pregabalin,  Zolpidem,  Galantamine,
Levetiracetam, Premipexole were reaching the market as an attempt to treat CNS diseases
and disorders. In the present study we have been selected Pregabalin and Zolpidem for the
quantitative determination. The main purpose of selecting those drugs was according to the
literature survey very few chromatographic and spectrophotometric method were developed
and still there was lot of scope to develop many analytical methods for the determination of
those drugs.
DRUG PROFILE
PREGABALIN
IUPAC Name : [S-[+]-3-isobutyl  GABA  or  (S)-3-(amino  methyl)-5-
methylhexanoic acid. 
Structural Formula :
Chemical formula : C8H17N  O2 
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Molecular Mass : 159.23 g/mol.                           
Description : Pregabalin is a white to off-white crystalline solid
Solubility : Freely soluble in water and methanol
Melting point : 127-1340C
Category :  Pregabalin is an anticonvulsant and used in treatment of diabetic
neuropathy.
Storage : Pregabalin should be kept in well closed container, protected from
light.
Indication :  For  management  of  neuropathic  pain  associated  with  diabetic
peripheral neuropathy and postherpeutic neuralgia. 
Mechanism of Action: Pregabalin binds with high affinity to the α-2-delta site (an auxiliary
subunit  of  voltage-gated  calcium  channels)  in  central  nervous
system tissues. Although the mechanism of action of pregabalin is
unknown,  results  with  genetically  modified  mice  and  with
compounds structurally related to pregabalin (such as gabapentin)
suggest that binding to the alpha2-delta subunit may be involved in
pregabalin’s  antinociceptive  and  antiseizure  effects  in  animal
models. In vitro, pregabalin reduces the calcium-dependent release
of  several  neurotransmitters,  possibly  by  modulation  of  calcium
channel function.
Drug Interactions : No pharmacokinetic interactions have been demonstrated in vivo.
But  some  potential  pharmacological interactions  with  opioids
(pregabalin  is  synergistic  with  opioids  in  lower  doses),
benzodiazepines,  barbiturates,  ethanol (alcohol),  and  other  drugs
that depress the central nervous system were noticed.
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Dosing : The recommended starting pregabalin dose for treating nerve pain
due  to  diabetic  neuropathy is  50  mg  three  times  daily.  The
recommended  starting  pregabalin  dose  for  controlling  partial
seizures in people with epilepsy is 75 mg twice daily or 50 mg three
times daily.
ZOLPIDEM
IUPAC Name : N, N, 6-Trimethyl-2-p-tolyl-imidazole (1,2-a)pyridine-3-acetamide
L-(+)-tartrate 
Structural Formula :
Chemical formula : (C19H21N3O) 2·C4H6O6
Molecular Mass : 764.88 g/mol.
Description : Zolpidem is a white to off-white, hygroscopic, crystalline powder.
Solubility : Freely soluble in water and sparingly soluble in methanol.
Melting point : 1950C
Category : Zolpidem is used as hypnotic.
Storage :  Zolpidem should  be  kept  in  air  tight  container,  protected  from
light.
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Mechanism of Action : Due to its selective binding, Zolpidem has very weak  anxiolytic,
myorelaxant and anticonvulsant properties but very strong hypnotic
properties.  Zolpidem  binds  with  high  affinity  and  acts  as  a  full
agonist at the α1 containing GABAA receptors, about 10-fold lower
affinity  for  those  containing  the  α2 and  α3 -  GABAA receptor
subunits, and with no appreciable affinity for  α5 subunit containing
receptors. ω1 type GABAA receptors are the α1 containing GABAA
receptors  and  ω2 GABAA receptors  are  the  α2,  α3,  α4,  α5 and  α6
containing  GABAA receptors.  ω1 GABAA receptors  are  primarily
found in the brain whereas ω2 receptors are primarily found in the
spine.  Thus zolpidem has  a  preferential  binding for  the GABAA-
benzodiazepine receptor complex in the brain but a low affinity for
the GABAA-benzodiazepine receptor complex in the spine. Like the
vast  majority  of  benzodiazepine-like  molecules,  zolpidem has  no
affinity  for  α4 and  α6 subunit-containing  receptors.  Zolpidem
positively modulates GABAA receptors, probably by increasing the
GABAA receptor  complexes  apparent  affinity for  GABA, without
affecting desensitization or peak current. Zolpidem increases  slow
wave sleep and caused no effect on stage 2 sleep in laboratory tests. 
Drug Interactions :  Notable  drug-drug  interactions  with  the  pharmacokinetics  of
zolpidem include the following drugs  chlorpromazine,  fluconazole,
imipramine,  itraconazole,  ketoconazole,  rifampicin,  ritonavir.
Interactions  with  carbamazepine and  phenytoin can  be  expected
based on their metabolic pathways but have not yet been studied.
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There does not appear to be any interaction between zolpidem and
cimetidine and rantidine.
Dosing :  The usual  dose  of  zolpidem in adults  is  5–10 mg.  For  healthy
adults, 10 mg is commonly recommended.
REVIEW OF LITERATURE
PREGABALIN
Rajinder Singh Gujral83 et al reported a method for the determination of pregabalin in bulk,
pharmaceutical  formulations  and  human  urine  samples  using  a  isocratic  reversed  phase
HPLC method. Separation was accomplished on a C18 5µm ODS hypersil column using a
methanol, acetonitrile and 0.02M di-potassium hydrogen ortho phosphate (3: 1: 16, V/V/V)
as mobile phase. The compound was eluted at a flow rate of 1 ml/min. For detection of the
pregabalin 210 nm wavelength was set. Linearity range of the method was 0.75-6.00 μg/ml.
Jadhav  S84 et  al reported  a  enantio  selective  high  performance  liquid  chromatographic
method, with precolumn derivitization with marfey’s  chiral  reagent, sodium 2,4-dinitro-5-
fluorophenyl-L-alamine amide for resolution of the enantiomers of a new anti epileptic drug,
pregabalin, in the bulk drug. The separation was accomplished using a reversed phase ODS
column with a mixture of aqueous 0.2% triethyl amine and acetonitrile (60:40) as mobile
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phase. The linearity range of the method was 750 to 7,500 ng/l. Recovery of R enantiomer
from bulk drug samples of pregabalin ranged from 97.5 to 101.76%.
Armagan Ona85 et al developed two spectrofluorimetric and spectrophotometric methods for
determination  of  pregabalin  in  bulk  drug  and  capsule.  Pregabalin  react  with  7-chloro-4-
nitrobenzofurazon which is  highly sensitive fluorogenic and chromogenic reagent  used in
many investigations. The relation between the absorbance at 460 nm and the concentration is
rectilinear  over  the  range  0.5–7.0 µg mL−1.  Measurement  was  also  made
spectrofluorimetrically at 558 nm after excitation at 460 nm. The fluorescence intensity was
directly proportional to the concentration over the range 40–400 ng/ml. The mean recovery
for  the  commercial  capsules  was  99.93%  and  99.96%  for  spectrophotometric  and
spectrofluorimetric study, respectively.
Onal Armagan86 et al reported three methods for the spectrophotometric determination of
pregabalin  in  pharmaceutical  preparations.  Two  methods  are  based  on  the  reaction  of
pregabalin as n-electron donors with 2, 3-dichloro -5,6-dicyano-1,4-benzoquinone(DDQ) and
7,7,8,8 tetra cyanoquinodimethane (TCNQ) as  pi-acceptor to give highly colored complex
species  which were quantitated spectrophotometrically. The third method is  based on the
interaction of ninhydrin with primary amine present in the pregabalin. The reaction product
was  measured spectrophotometrically at  495 nm, 841 nm, and 573 nm respectively.  The
linearity ranges of the three methods were 2.0-3.0 g/ml, 1.5-10 g/ml, and 40.0-180.0 μg/ml.
respectively. 
Vermeij TAC87 et al  presented a HPLC method for the simultaneous determination of the γ-
amino-n-butyric acid (GABA) derivatives, pregabalin, gabapentin and vigabatrin in human
serum  by  HPLC.  Serum  is  deproteinized  with  trichloroacetic  acid  and  aliquots  of  the
supernatant  are  precolumn  derivatized  with  o-phtaldialdehyde  (OPA)  and  3-
mercaptopropionic acid. The drugs are monitored using fluorescence detection. Separation is
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achieved on an Alltima 3C18 column using isocratic elution. The method is linear up to at
least 63 mg/l for PGB, 40 mg/l for GBP and 62 mg/l for VGB. 
Berry88 et al developed a HPLC method for assay of the new antiepileptic drug pregabalin in
serum/plasma. Acetone precipitation of the drug was carried out and derivitized with picryl
sulfonic acid (PSA) before chromatography on C8 column.  The linearity range of the method
was 2.8-8.2 mg/L at steady state.
Vermeij  TAC89 et  al developed  a  method  for  the  simultaneous  determination  of  seven
antiepileptic  drugs,  including  primidone,  Phenobarbital,  phenytoin,  carbamazepine,
lamotrigine,  hydroxycarbazepine and zonisamide in serum by HPLC-diode array detector
(DAD). Separation is achieved on an Alltima 3C18 analytical column using isocratic elution
with a mixture of acetonitrile, methanol and phosphate buffer at 45 °C as mobile phase.
Rajinder Singh Gujral90 et al developed a spectrophotometric method for determination of
pregabalin in bulk, formulations and in human urine samples. The method is based on the
reaction  of  drug  with  the  mixture  of  potassium  iodate  and  potassium  iodide  and  the
absorbance was measured at 353 nm. 
Hesam Salem91 studied the charge transfer reaction of pregabalin as n-electron donor with
various  pi-acceptors:  7,7,8,8-tetracyanoquinodimethane  (TCNQ),  2,3-dichlore-5,6-dicyano-
1,4-benzoquinone  (DDQ),  2,5-dichloro-3,6-dihydroxy-1,4benzoquinone  and  2,3,5,6-
tetrchloro-1,4-benzoquinone.  Different  colored  charge-transfer  complexes  were  obtained
which are utilized in the development of  spectrophotometric methods for the analysis of
pregabalin in pure form as well as formulations. The linearity range of the method was 8-400
µg/ml. The recovery percentages of the method ranged from 100.19±0.83 to100.50±0.53.
Uttam Mandal92 et al developed a bioanalytical method for determination of pregabalin in
human plasma. This analytical method consists in the precipitation of plasma sample with
trichloro acetic acid (20% v/v solution in water), followed by the determination of pregabalin
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by an LC-MS-MS method using gabapentin as internal standard. Separation was achieved on
a Gemini C18 50 mm · 2.0 mm (3 lm) column with an isocratic mobile phase consisting of
methanol–water (98:2, v/v) with 0.5% v/v formic acid. Protonated ions formed by a turbo
ionspray in positive mode were used to detect analyte and internal standard. The MS-MS
detection was by monitoring the fragmentation of 160       55.1 (m/z) for pregabalin and 172.2
67.1 (m/z) for gabapentin on a triple quadrupole mass spectrometer.
Vaidya  V93 et  al developed  a  method  to  quantify  pregabalin  in  human  plasma  using
metaxalone as the internal standard. Sample preparation involved simple protein precipitation
by using  acetonitrile  as  solvent.  Chromatography was  performed isocratically  on  thermo
hypurity C18 5 μm analytical column. The assay of pregabalin was linear calibration curve
over the range 10.000–10000.000 ng/ml.
Rasha Abdel94 et al developed three spectrofluorimetric and spectrophotometric methods for
the determination of pregabalin. Pregabalin as a primary amine reacts with fluorescamine to
yield  a  fluorescent  product,  with  2,4-dinitrofluorobenzene  and  2,3,5,6-tetrachloro-1,4-
benzoquinone  in aqueous alkaline buffered media to form colored products which could be
measured spectrophotometrically. The optimum conditions for each reaction were ascertained
and the methods were applied for  the determination of  pregabalin over  the concentration
range  of  20-280  ng/ml  and  1  –  7  µg/ml  for  spectrofluorimetry  and  spectrophotometry
respectively with good correlation (≥0.999). 
Kannapan N95 et  al developed a  RP-HPLC method for  determination of  pregabalin  and
methylcobalamine combined in capsule dosage form. Separation was achieved isocratically
using Waters allaiance 2695 seperation module, C18 column (250 х 4.6 mm, 5mcg/ml) at
temperature 40°C. Flow rate selected was 1ml/min using UV visible PDA detector at 210 nm.
Mobile  phase  was  prepared  using  ammonium  dihydrogen-o-phosphate  (buffer  6.0),
acetonitrile and methanol in the ratio of 75:15:10 which gave better resolution and sensitivity.
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The method was found to be linear in the range of 3200-4800 mcg/ml and 16-24 mcg/ml for
pregabalin and methylcobalamine.
Rajinder  Singh  Gujral96 et  al developed  a  UV  spectrophotometric  method  for  the
determination  of  pregabalin  in  bulk,  pharmaceutical  formulations  and  in  human  urine
samples. The method was linear in the range of 0.5–5.0 µg/ml. The absorbance was measured
at 210 nm. 
ZOLPIDEM
Hempel G97 et al reported a method for the determination of zolpidem and its main metabo-
lites in urine without extraction using capillary electrophoresis with UV laser-induced fluo-
rescence detection with a He-Cd laser. The separation is carried out within 10 min, and the
limit of detection is 2 ng/ml. 
Bhatt J98 et al developed a method for quantification of zolpidem in human plasma using liq-
uid chromatography-electrospray ionization tandem mass  spectrometry (LC-ESI MS/MS).
Es-citalopram was used as an internal standard. Zolpidem and internal standard in plasma
sample was extracted using solid-phase extraction cartridge. The samples were injected into a
C8 reversed-phase column and the mobile phase used was acetonitrile-ammonium acetate
(pH 4.6; 10 mm) (80:20, v/v) at a flow rate of 0.7 ml/min. Using MS/MS in the selected reac-
tion-monitoring (SRM) mode, zolpidem and Es-citalopram were detected without any inter-
ference from human plasma matrix. The proposed method was validated in the linear range
2.5-300 ng/ml.
 Keller T99 et al reported a method for analysing and determining the zolpidem concentration
in post-mortem specimens by GC-MS method. Quantitation of zolpidem was performed by
ethyl acetate extraction from alkalinized body fluids before GC/MS analysis. The analyses
were performed without any complex sample clean-up steps and with little sample material. 
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 Stanke F100 et al developed  a method for the simultaneous determination of zolpidem and
zopiclone in human plasma. After a liquid-liquid extraction, the extract  is  injected into a
capillary  gas  chromatograph  with  an  OV-1  fused-silica  column  coupled  to  a  nitrogen-
phosphorus  detector.  The detection limits are 1 and 2 ng/ml for  zolpidem and zopiclone,
respectively. 
Debruyne. D101 et al developed a gas chromatographic method using a short, high-resolution
capillary column connected to a specific thermionic detector and requiring a simple and short
extraction step without evaporation was developed for the rapid and precise determination of
zolpidem and zopiclone in serum. The linearity range was between 5 and 200 ng/ml. The
method was validated and then used to analyze zolpidem serum concentrations in nine rabbits
after oral  administration of 0.5 mg/kg and zopiclone serum concentrations in six  patients
treated orally with a 7.5-g dose.
 Nirogi RVS102 et al developed a HPLC method with fluorescence detection for quantitation
of zolpidem in human plasma. Following a single-step liquid–liquid extraction, the analyte
and internal standard (quinine) were separated using an isocratic mobile phase on a reversed-
phase C18 column. The linearity range of the method was 1.8–288 ng/ml. 
Laviana L103 et  al  reported  a  HPLC assay with diode-array detection  for  the  in-process
control of zolpidem synthesis and for the analysis of the drug and its synthetic intermediates.
The  separation  was  achieved  by  reversed-phase  Kromasil  C-18  (150  mm)  column.
Acetonitrile and 0.02 M NH4OAc adjusted to pH 8.0 was used as mobile phase with flow rate
1.0 ml/min.
Ptacek P104 et al developed a method for the determination of zolpidem in human plasma by
HPLC.  This  method  involves  protein  precipitation  with  methanol  and  reversed-phase
chromatography  with  fluorescence  detection  (excitation  wavelength  244  nm,  emission
wavelength 388 nm). Methanol- 30 mM dihydrogen potassium phosphate-triethylamine are
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used as the mobile phase in the ratio of 30:69:1 and the calibration curve is linear up to 400
ng/ml.
Qiao Wang105 et al a single-solvent extraction step high-performance liquid chromatographic
method for quantitation of zolpidem in rat serum. The separation was achieved by 2.1 mm
I.D. reversed-phase OD-5-100 C18 column, 5 µm particle size with an isocratic mobile phase
consisting  of  methanol–acetonitrile–  tetrabutyl  ammonium  phosphate  (13:10:77,  v/v/v).
Ultraviolet  detector  was  operated  at  240  nm.  The  recovery  was  greater  than  87%  with
analysis performed in 12 min. 
El Zeany BA106 et al reported two methods for the determination of zolpidem hemitartrate in
presence of its degradation product. The first method was a TLC-UV densitometric one in
which the mobile phase methanol: water (20:80) was used for developing the TLC plates.
Linearity range was 0.5-4 microg/spot with mean recovery percentage (99.98+/-0.988) %.
The  second  method  was  an  HPLC  method.  HPLC  was  performed  on  a  bondapack  C18
column.  The  mobile  phase  was  composed  of  a  mixture  of  acetonitrile-0.01  M  KH2PO4
(40:60). The pH was adjusted to 3.5+/-0.1. Flow rate was 1.2 ml/min. The linearity range was
0.5-5 µg/ml with UV detection at 245 nm. 
Ring PR107,  et al developed a HPLC method for the determination of zolpidem in human
plasma. Zolpidem and the trazodone (internal standard) were extracted from human plasma.
Separation was achieved on a C18 column (150 x 4.6 mm, 5microm) with a mobile phase
composed  of  acetonitrile:  50  mM  potassium  phosphate  monobasic  at  pH  6.0  (4:6  v/v)
Detection was by fluorescence,  with  excitation at  254 nm and  emission at  400 nm. The
linearity range 1-400 ng/ml for zolpidem in human plasma.
Rajiv  Chomwal108 et  al developed  four  spectrophotometric  methods  for  estimation  of
Zolpidem tartrate  in  tablet  dosage forms.  The four methods were developed using dyes,
bromo  phenol  red,  bromo  cresol  purple,  bromo  cresol  green  and  bromo  phenol  blue
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respectively. The linearity ranges of four methods were 5-30 µg/ml, 5-30 µg/ml, 10-50 µg/ml
and 5-40 µg/ml respectively. Absorbance maxima measured at 407 nm, 417 nm, 412 nm and
415 nm respectively.
Patil KS109 et al  reported a spectrophotometric method for estimation of Zolpidem tartrate in
bulk and pharmaceutical  dosage forms. Zolpidem tartrate  shows maximum absorbance at
238.5. Beer’s law was obeyed in the concentration range of 2-16 µg/ml. The limit of detection
and  limit  of  quantification  were  found  to  be  0.038152  µg/ml  and  0.114577  µg/ml
respectively.
REAGENTS
NQS REAGENT
Mahmoud AM110 et al developed a spectrophotometric and spectrofluorimetric method for
the determination of amantadine hydrochloride (AMD) in capsules and plasma. The methods
were based on the condensation of AMD with 1, 2-naphthoquinone-4-sulphonate (NQS) in an
alkaline  medium  to  form  an  orange-colored  product.  The  spectrophotometric  method
involved the measurement of the colored product at 460 nm. The spectrofluorimetric method
involved  the  reduction  of  the  product  with  potassium  borohydride,  and  the  subsequent
measurement  of  the  formed  fluorescent  reduced  AMD-NQS  product  at  382  nm  after
excitation  at  293  nm.  Linearity  ranges  were  5–80  and  0.05–10  µg/ml  for  the
spectrophotometric and spectrofluorimetric methods, respectively. 
Huai  You  Wang111 et  al developed  a  spectrophotometric  method  for  determination  of
dapsone. The dapsone reacts with sodium 1, 2-naphthoquinone-4-sulfonic in pH 6.98 buffer
solution to form a salmon pink compound, and its maximum absorption wavelength is at 525
nm. The linearity range was 0.40 to 10 µg/ml. 
SANGERS REAGENT
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Abdel  Razak  O112 et  al developed  a  method  for  spectrophotometric  and  polarographic
determination of  enalapril  and  lisinopril  using 2,  4-dinitrofluorobenzene.  The reaction of
enalapril maleate and lisinopril with 2,4-dinitrofluorobenzene has been used to form colored
products and polarographically active derivatives. The different experimental conditions have
been optimized. 
MBTH REAGENT AND PARACHLORANILIC ACID
Alfaraj  NA113 et  al developed  spectrophotometric  methods  for  the  determination  of
mefenamic acid. The first method is based on the reaction of mefenamic acid as N-donor with
p-chloranilic  acid  as  a  pi-acceptor.  A red  colour  product  shows  peak  at  520  nm and  its
absorbance is linear with concentration over the range 10-300 µg/mL. The second method is
based on the formation of an oxidative coupling product by the reaction of mefenamic acid
with 3-methylbenzo-thiazolin-2-one hydrazone as a chromogenic reagent in presence of ferric
chloride solution. A green colour product shows peak at 602 nm and its absorbance is linear
with concentration over the range 1-6 µg/ml.  
Manish majumder114 et al developed a visible spectrophotometric method for the estimation
of  tinofovir  in  bulk  and  in  pharmaceutical  preparations.  Tinofovir  was  subjected  to  acid
hydrolysis and this acid hydrolyzed drug was used for the estimation. This method is based
on  the  reaction  with  3-methyl-2-benzothiazolinone  hydrazone  in  the  presence  of  ferric
chloride, to form a colored species with a λmax at 628.5 nm.  Beer’s law is obeyed in the
concentration range of 5-40 µg/ml. 
GIBB’S REAGENT
Chilukuri sastry SP115 et al reported two visible spectrophotometric methods for the assay of
cefadroxil.  First  method  was  based  on  the  reaction  of  cefadroxil  with  3-methyl-2-
benzothiazolinone hydrazone hydrochloride in the presence of ceric ammonium sulphate and
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the formed colored species was detected at 410 nm. Second method based on reaction of
cefadroxil  with  2,6-dichloroquinone-4-chlorimideand  the  formed  colored  species  was
detected at 620 nm. Beer’s law was obeyed in the concentration range of 1.0-6.0 and 1.0-6.0
µg/ml for first and second methods respectively. 
BM REAGENT
Gurupadayya BM116 et al developed a method for the quantitative estimation of pramipexole
dihydrochloride  drug  and  its  formulations  (Tablets).  This  method  was  based  on  the
diazotization of primary amine group of pramipexole with sodium nitrate and hydrochloric
acid followed by coupling with N-(1-napthyl) ethylene diamine hydrochloride (BM reagent)
to form a colored chromogen with a characteristic absorption maximum at 616 nm. Beer’s
law is obeyed in concentrations ranging of 4-20 µg/ml.
2,4-DNP REAGENT
Padmarajaiah  Nagaraja117 et  al developed  a  spectrophotometric  method  for  the
determination of four phenolic drugs; salbutamol, ritodrine, amoxicillin and isoxsuprine. The
method  is  based  on  the  oxidation  of  2,  4-  Dinitrophenylhydrazine  and  coupling  of  the
oxidized  product  with  drugs  to  give  intensely  colored  chromogen.  Under  the  proposed
optimum condition, Beer’s law was obeyed in the concentration range of 2.5-17, 2-29, 4-33
and 5-30 µg/ml for salbutamol, ritodrine, amoxicillin and isoxsuprine respectively.
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OBJECTIVES 
The primary objective of the proposed work was to
 Develop  new,  simple,  sensitive,  accurate,  and  economical  spectrophotometric
methods for the estimation of CNS acting drugs.
 Develop new, sensitive, accurate and economical  gas chromatography methods for
estimation of CNS acting drugs.
 Validate  the  developed  methods  and  apply  them  for  estimation  of  commercially
available formulations.    
Pregabalin and zolpidem are the drugs belonging to CNS category which are used
against  epilepsy and insomnia respectively. Pregabalin is  an  anticonvulsant drug used for
neuropathic pain and as an adjunct therapy for  partial seizures with or without secondary
generalization in  adults. Zolpidem is  a  prescription  medication used  for  the  short-term
treatment of insomnia, as well as some brain disorders. It is a short-acting nonbenzodiazepine
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hypnotic that potentiates gamma-amino butyric acid (GABA), an inhibitory neurotransmitter
by binding to GABAA receptors at the same location as benzodiazepines.
Literature survey reveals that very few methods have been developed for pregabalin
and  zolpidem.  In  the  present  investigation  made  attempts  to  develop  some  new
spectrophotometric  methods  and  chromatographic  methods  for  pregabalin  and  zolpidem,
which  are  highly  sensitive,  accurate,  precise  and  economical.  Since  very  few  analytical
methods have been reported for the quantitative estimation of these drugs its necessary for the
investigation of new analytical methods for estimation of pregabalin and zolpidem in bulk
drugs and pharmaceutical formulations.
Validation of the methods was carried out in accordance with ICH guideline for the
assay of active ingredients. The method was validated for parameters like accuracy, linearity,
precision, specificity, system suitability.
The primary objective of validation in the analysis of a drug is to design and develop
methods preferably instrumental ones such as UV spectrophotometric / GC that are sensitive
and reproducible, when applied for analysis of marketed formulations.
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MATERIALS AND METHODS
PART A: 
UV-VISIBLE SPECTROPHOTOMETRIC METHODS FOR PREGABALIN
METHOD 1: Estimation of pregabalin by NQS reagent
METHOD 2: Estimation of pregabalin by Sanger’s reagent
METHOD 3: Estimation of pregabalin by MBTH reagent
METHOD 4: Estimation of pregabalin by Gibb’s reagent
METHOD 5: Estimation of pregabalin by BM reagent
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METHOD 6: Estimation of pregabalin by 2, 4-DNP reagent
UV-VISIBLE SPECTROPHOTOMETRIC METHODS FOR ZOLPIDEM
METHOD 7: Estimation of zolpidem by MBTH reagent
METHOD 8: Estimation of zolpidem by 2, 4-DNP 
METHOD 9: Estimation of zolpidem by p-CA reagent
PART B: 
 GAS CHROMATOGRAPHY METHOD
METHOD 10: Derivatization of pregabalin by Gas chromatography
METHOD 11: Derivatization of zolpidem by Gas chromatography
PART A: UV- VISIBLE SPECTROPHOTOMERTIC METHODS
METHOD 1 (ESTIMATION OF PREGABALIN BY NQS REAGENT)
1.1 PRINCIPLE INVOLVED
Pregabalin  possesses  different  functional  groups  such  as  carboxylic  acid  and  free
amine group. An attempt has been made to determine pregabalin by reacting the amine group
with the reagent. The reaction involves replacement of SO3Na group in NQS by the amino
group in pregabalin in alkaline condition which is as shown below (Scheme 1). The reaction
results in an orange coloured complex with absorption maximum at 485 nm.
1.2 REACTION INVOLVED 
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Scheme 1: Reaction of NQS reagent and PGB
1.3 REAGENTS USED
1.3.1 Sodium Hydroxide 0.01N
0.2 g of sodium hydroxide was weighed accurately and dissolved in distilled water in
500 ml volumetric flask and volume was made up to mark with distilled water.
1.3.2 NQS 0.5 % (w/v)
0.50 g of NQS was weighed accurately and dissolved in distilled water in 100 ml
volumetric flask and volume was made up to mark with distilled water.
1.4 PREPARATION OF STANDARD CALIBRATION CURVE 
1.4.1 Preparation of standard stock solution
Accurately weighed 100 mg of  pregabalin  (bulk drug) was dissolved in 40 ml of
warm double distilled water in 100 ml volumetric flask and sonicated for about 15 min to
enhance the solubility and volume was made up to  the mark with double distilled water to
obtain a final concentration of  1000 µg/ml (solution A).
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From  the  above  stock  solution  A 10  ml  of  aliquot  was  pipetted  out  in  100  ml
volumetric flask and the volume was made up to the mark with double distilled water to
obtain the final concentration of 100 µg/ml  (Stock solution B).
1.4.2 Preparation of calibration curve
Aliquots of pregabalin ranging from 0.5- 4.5 ml (5- 45µg/ml) were pipetted into a
series of 10 ml volumetric flask. To each flask, 1.0 ml of NQS solution and 1.0 ml of 0.01N
sodium hydroxide were added and diluted to volume with distilled water. The reaction was
allowed to proceed at room temperature. The absorption spectrum of PGB was done and it
showed  485  nm  as  the  maximum  absorption  point  (Fig.1).  The  calibration  curve  was
constructed by plotting absorbance against the concentration of PGB. The linearity range or
Beer’s range follows in the range between 5- 45 µg/ml (Fig.2). The content of PGB was
calculated from the calibration graph.
1.5 ANALYSIS OF CAPSULE DOSAGE FORM
Five  capsules  (Pregeb  –  75mg)  were  weighed  and  their  contents  were  mixed
thoroughly. An accurately weighed portion of powder equivalent to the 100 mg of PGB was
weighed into a 100 ml volumetric flask containing about 75 ml of warm distilled water. It
was shaken thoroughly for about 5-10 min, filtered thorough whatman filter paper to remove
insoluble matter and diluted to the mark with distilled water to 1000 µg/ml solution (stock
solution A). From the above stock solution 10.0 ml was pipetted out in 100 ml volumetric
flask  and  the  volume  was  made  up  with  warm  double  distilled  water  to  obtain  final
concentration of 100 µg/ml. From stock solution B 4.0 ml of solution was pipetted into a 10
ml volumetric flask and then resultant solution is also analysed as per the procedure and were
statistically validated. 
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Fig.1. Absorption spectra of NQS with PGB against the reagent blank
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                             Fig.2. Calibration graph of PGB with NQS reagent
METHOD 2 (ESTIMATION OF PREGABALIN BY SANGERS REAGENT)
2.1 PRINCIPLE INVOLVED
In  this method an attempt has been made to determine pregabalin by reacting the
amine group with sangers reagent. The reaction involves replacement of fluorine in sangers
reagent by the amine group in pregabalin in alkaline condition which is as shown below
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(Scheme 2). The reaction results in a yellow coloured complex with absorption maximum at
353 nm.
2.2 REACTION INVOLVED 
Scheme 2: Reaction of sangers reagent and PGB
2.3 REAGENTS USED
2.3.1 Sanger’s reagent 0.5 %( w/v)
0.5  g  of  Sanger’s  reagent  was  accurately  weighed  and  transferred  into  a  100  ml
calibrated flask, dissolved in methanol, and make up the volume up to the mark to obtain a
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solution of 0.5% (w/v). Reagent should be protected from light during use and should be
handled carefully since it is a skin irritant. If stored in a refrigerator it is stable for 4 months.
2.3.2 Borate buffer pH 9
Placed 50 ml of the 0.2 M boric acid and potassium chloride in 200 ml volumetric
flask, added 20.0 ml of 0.2 M NaOH and made to the mark with water.
2.4 PREPARATION OF STANDARD CALIBRATION CURVE 
2.4.1 Preparation of standard stock solution
Accurately weighed 100.0 mg of pregabalin (bulk drug) was dissolved in 40.0 ml of
methanol in 100 ml volumetric flask and sonicated for about 15 min to enhance the solubility
and volume was made up to the mark with methanol to obtain a final concentration of 1000
µg/ml (solution A).
From  the  above  stock  solution  A 10  ml  of  aliquot  was  pipetted  out  in  100  ml
volumetric flask and the volume was made up to the mark with methanol to obtain the final
concentration of 100 µg/ml  ( solution B).
2.4.2 Preparation of calibration curve
Aliquots of pregabalin ranging from 0.5- 1.3 ml (1.0 - 13.0 µg/ml) were pipetted into
as series of 10 ml volumetric flask. To each flask, 1.0 ml of sanger’s solution and 0.2 ml of
borate buffer pH 9 were added. The mixture was then gently shaken and heated for 900C for
10 minutes until the appearance of yellow colour. The contents were diluted up to 10 ml with
methanol. The absorption spectrum of PGB was done and it showed 353 nm as the maximum
absorption  point  (Fig.3).  The  calibration  curve  was  constructed  by  plotting  absorbance
against the initial concentration of PGB. The linearity range or Beer’s range follows in the
range  between  5.0-  13.0  µg/ml (Fig.4).  The  content  of  PGB  was  calculated  from  the
calibration graph.
2.5 ANALYSIS OF CAPSULE DOSAGE FORM
Five capsules were weighed and their contents were mixed thoroughly. An accurately
weighed portion of powder equivalent to the 100 mg of PGB was weighed into a 100 ml
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volumetric flask containing about 50 ml of methanol. It was shaken thoroughly for about 5-
10 min, filtered through whatman filter paper to remove insoluble matter and diluted to the
mark with methanol to prepare 1000 µg/ml solution (stock solution A). From the above stock
solution 10.0 ml was pipetted out in 100 ml volumetric flask and the volume was made up
with methanol to obtain final concentration of 100 µg/ml. From the above stock pipetted out
1 ml in 10 ml volumetric flask and the resultant solution was analysed as per the procedure
and were statistically validated. 
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Fig.3. Absorption spectra of sangers with PGB against the reagent blank
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Fig.4. Calibration graph of PGB with Sangers reagent
METHOD 3 (ESTIMATION OF PREGABALIN BY MBTH REAGENT)
3.1 PRINCIPLE INVOLVED
In  this  method PGB reacts with MBTH in the presence of  FeCl3 to  give a green
colored product (Scheme 3). This is an iron catalyzed oxidative coupling reaction of  MBTH
with the drug. Under the reaction conditions, on oxidation, MBTH loses two electrons and
one proton forming an electrophilic intermediate, which is the active coupling species. This
intermediate undergoes electrophilic substitution with the drug to form green colored product
with absorption maximum of 668 nm. 
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3.2 REACTION INVOLVED 
Scheme
3:
3.3 REAGENTS USED
3.3.1 3-Methyl-2-Benzthiazolinone hydrochloride (MBTH) 0.5 %( w/v)
0.5 g of MBTH reagent was accurately weighed transferred into a 100 ml calibrated
flask, dissolved in distilled water and made to the mark to obtain a solution of 0.5% (w/v).
3.3.2 Ferric chloride (1%)
It was prepared by dissolving 1.0 g of ferric chloride in 100 ml of distilled water.
3.4 PREPARATION OF STANDARD CALIBRATION CURVE 
3.4.1 Preparation of standard stock solution
Accurately weighed 100.0 mg of pregabalin (bulk drug) was dissolved in 40.0 ml of
methanol  in 100 ml volumetric flask and sonicated for about 15 min to enhance the solubility
and volume was made up to the mark with methanol to obtain final concentration of 1.0
mg/ml.
3.4.2 Preparation of calibration curve
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Aliquots of pregabalin ranging from 0.5- 3.5 ml (50- 350 µg/ml) were pipetted into a
series of 10 ml volumetric flask. To each flask 2 ml of MBTH, 2 ml of ferric chloride was
added and the volume was made to the mark with distilled water and allowed to stand for 20
minutes. The absorbance of each solution was measured at 668 nm against the reagent blank.
The  colored  species  was  stable  for  2  hours  and  the  amount  of  drug  in  the  sample  was
computed from its calibration curve represented in Fig. 5. and Fig. 6.
3.5 ANALYSIS OF CAPSULE DOSAGE FORM
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Five  capsules  were  weighed  and
their contents are mixed thoroughly. An accurately weighed portion of powder equivalent to
the 100 mg of PGB was weighed into a 100 ml volumetric flask containing about 50 ml of
methanol. It was shaken thoroughly for about 5-10 minutes, filtered through a whatman filter
paper to remove insoluble matter and diluted to the mark with methanol to prepare 1000
µg/ml solution. 1.0 ml of the above solution was taken from above stock solution in to a 10
ml volumetric flask. Then to that solution 2 ml of MBTH and 2 ml of FeCl3 were added. The
mixture was then gently shaken and the appearance of green color occurs. The contents were
diluted up to 10 ml with distilled water.
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Fig.5. Absorption spectra of MBTH
with PGB against the reagent blank
Fig.6. Calibration graph of PGB with MBTH reagent
METHOD 4 (ESTIMATION OF PREGABALIN BY GIBB’S REAGENT)
4.1 PRINCIPLE INVOLVED
In  this method an attempt has been made to determine pregabalin by reacting the
amine group with Gibb’s reagent.  The reaction involves  oxidation of the pregabalin with
reagent (Scheme 4). The colored product had absorbance maxima at 400 nm.
4.2 REACTION INVOLVED 
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Scheme 4: Reaction of Gibb’s
reagent and PGB
4.3 REAGENTS USED
4.3.1 2, 6-Dichloroquinone-chlorimide 0.5 %( w/v):
0.5 g of  Gibb’s reagent was accurately weighed transferred into a 100 ml calibrated
flask,  dissolved in 10 ml of methanol,  and made to the mark with methanol to obtain a
solution of 0.5% (w/v). The solution was freshly prepared and protected from light.
4.4 PREPARATION OF STANDARD CALIBRATION CURVE 
4.4.1 Preparation of standard stock solution
Accurately weighed 100.0 mg of pregabalin (bulk drug) was dissolved in 40.0 ml of
methanol  in 100 ml volumetric flask and sonicated for about 15 min to enhance the solubility
and volume was made up to the mark with methanol to obtain final concentration of 1.0
mg/ml.
4.4.2 Preparation of calibration curve
Aliquots of pregabalin ranging from 0.5- 3.5 ml (50- 350 µg/ml) were pipetted into a
series of 10 ml volumetric flask. To those solutions 1.5 ml of 0.5% Gibb’s reagent was added.
The mixture was then kept aside for 5 minutes and heated for 10 minutes. The contents were
diluted to 10 ml with methanol.  The absorbance of each solution was measured at 400 nm
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against the reagent blank. The colored species was stable for 2 hours and the amount of drug
in the sample was computed from its calibration curve represented in Fig. 7 and Fig. 8.
4.5 ANALYSIS OF CAPSULE DOSAGE FORM
Five capsules were weighed and their contents are mixed thoroughly. An accurately
weighed portion of powder equivalent to the 100 mg of PGB was weighed into a 100 ml
volumetric flask containing about 75 ml of methanol. It was shaken thoroughly for about 5-
10 minutes, filtered through a whatman filter paper to remove insoluble matter and diluted to
the mark with methanol to prepare 1000 µg/ml  solution. An aliquot of  this  solution was
diluted with methanol to obtain a concentration of 50 µg/ml. Then to that solution, 1 ml of
Gibb’s reagent was added and then gently shaken. The contents were diluted up to 10 ml with
methanol.
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             Fig.7. Absorption spectra of Gibb’s with PGB against the reagent blank
53
0 50 100 150 200 250 300 350 400
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
   
            Fig.8. Calibration graph of PGB with Gibb’s reagent
METHOD 5 (ESTIMATION OF PREGABALIN BY BM REAGENT)
5.1 PRINCIPLE INVOLVED
In  this  method  the  reaction  between  pregabalin  and  BM  reagent  depends  on
diazotization  of  drugs  with  nitrous  acid,  to  form  diazotized  compound,  followed  by  its
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coupling with  N-(1-naphthyl) ethylene- diamine dihydrochloride [Bratton-Marshal reagent]
to form a violet colored chromogen (Scheme 5) with absorption maximum of 471 nm.
5.2 REACTION INVOLVED 
5.3 REAGENTS USED
5.3.1 2N HCl:
It was prepared by dissolving 8.5 ml of hydrochloric acid in 100 ml of water.
 5.3.2 Sodium nitrite 0.3 % (w/v):
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A 0.3% (w/v) sodium nitrite was prepared by dissolving 0.3 g in 100 ml of distilled
water.
5.3.3 Ammonium sulfamate 0.1 % (w/v):
A 0.1 % (w/v) ammonium sulfamate was prepared by dissolving 0.1 g in 100 ml of
distilled water.
5.3.4 N-(1-naphthyl) ethylene- diamine dihydrochloride [BMR] 0.2 % (w/v):
A 0.2 % (w/v) BM reagent was prepared by dissolving 0.2 g in 100 ml of distilled
water.
5.4 PREPARATION OF STANDARD CALIBRATION CURVE 
5.4.1 Preparation of standard stock solution
Accurately weighed 100.0 mg of pregabalin (bulk drug) was dissolved in 40.0 ml of
methanol  in 100 ml volumetric flask and sonicated for about 15 min to enhance the solubility
and volume was made up to the mark with methanol to obtain final concentration of 1.0
mg/ml.
5.4.2 Preparation of calibration curve
Aliquots of pregabalin ranging from 0.5- 3.5 ml (50- 350 µg/ml) were pipetted into a
series of 10 ml volumetric flask. To each flask, 1.0 ml of hydrochloric acid (2 N) and 1.0 ml
of sodium nitrite (0.3 % w/v) were added and a reaction time of 10 minutes to these solutions
at 0-5˚ C was given for the completion of the reaction. Next, 1.0 ml of ammonium sulfamate
(0.1 % w/v) was added to each flask with gentle shaking after 1 minute, 1 ml of BMR reagent
(0.2  % w/v)  was  added,  and kept  for  20 minutes.  Finally the volume in  each  flask was
brought  up  to  the  10  ml  mark  with  distilled  water.  The  absorbance  of  violet-coloured
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chromogen was measured at 471 nm. The amount of drug in the sample was computed from
its calibration curve represented in Fig. 9 and Fig. 10.
5.5 ANALYSIS O DOSAGE FORM
Five capsules were weighed and their contents are mixed thoroughly. An accurately
weighed portion of powder equivalent to the 100 mg of PGB was weighed into a 100 ml
volumetric flask containing about 75 ml of methanol. It was shaken thoroughly for about 5-
10 minutes, filtered through a whatman filter paper to remove insoluble matter and diluted to
the mark with methanol to prepare 1000 µg/ml solution. From the above stock solution 0.5 ml
was taken in a 10 ml volumetric flask and the resultant solution was analysed as per the
procedure and were statistically validated. 
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Fig .9. Absorption spectra of BM reagent with PGB against the reagent blank
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Fig .10. Calibration graph of PGB with BM reagent
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METHOD 6 (ESTIMATION OF PREGABALIN BY 2, 4 – DNP REAGENT)
6.1 PRINCIPLE INVOLVED
In this method  2, 4-DNP is oxidized by potassium iodate to give diazonium cation
which reacts with carboxylic group of the drug by electrophilic substitution to give deep
colored chromogen (Scheme 6) with absorption maximum of 461 nm.
6.2 REACTION INVOLVED 
Scheme 6: Reaction of 2,4-DNP reagent and PGB
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6.3 REAGENTS USED
6.3.1 2, 4-Dinitrophenyl hydrazine (2, 4-DNP) 0.08 %( w/v)
A 0.08% w/v of the reagent solution was freshly prepared by dissolving 0.08 g of 2, 4-
DNP in 2 ml of concentrated sulphuric acid and diluting to 100 ml with water.
6.3.2 10N Sodium hydroxide solution.
40 g of sodium hydroxide was dissolved in 100 ml of distilled water.
6.3.3 Potassium iodate 4 % (w/v)
A 4% w/v potassium iodate solution was prepared by dissolving 4 g in 100 ml of
distilled water.
6.4 PREPARATION OF STANDARD CALIBRATION CURVE 
6.4.1 Preparation of standard stock solution
Accurately weighed 100.0 mg of pregabalin (bulk drug) was dissolved in 40.0 ml of
warm double distilled water in 100 ml volumetric flask and sonicated for about 15 min to
enhance the solubility and volume was made up to  the mark with double distilled water to
obtain final concentration of 1000 µg/ml (Stock solution).
6.4.2 Preparation of calibration curve
Aliquots of pregabalin ranging from 0.5- 3.5 ml (50- 350 µg/ml) were pipetted into a
series of  10 ml  volumetric  flask.  To these solutions 1.5  ml of  2,  4-DNP  and 1.5 ml of
potassium iodate
 
were added, which were made alkaline by adding 1 ml each of sodium
hydroxide. The red color hence developed was further diluted to the volume with water. The
amount of drug in the sample was computed from its calibration curve represented in Fig. 11
and Fig. 12.
6.5 ANALYSIS O DOSAGE FORM
Five capsules were weighed and their contents are mixed thoroughly. An accurately
weighed portion of powder equivalent to the 100 mg of PGB was weighed into a 100 ml
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volumetric flask containing about 75 ml of distilled water. It was shaken thoroughly for about
5-10 min, filtered through whatman filter paper to remove insoluble matter and diluted to the
mark with distilled water to prepare 1000 µg/ml solution. From the above stock solution 1 ml
was taken into 10 ml volumetric flask. Then to that solution 1.5 ml of 2, 4-DNP was added,
and 1.5 ml of potassium iodate and 1 ml of 10 N sodium hydroxide was added. The mixture
was then gently shaken until the appearance of red color. The contents were diluted up to 10
ml with distilled water to obtain 100 µg/ml concentration.
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Fig.11. absorption spectra of 2, 4- DNP with PGB against the reagent blank
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Fig. 12. Calibration graph of PGB with 2, 4-DNP
METHOD 7 (ESTIMATION OF ZOLPIDEM BY MBTH REAGENT)
7.1 PRINCIPLE INVOLVED
Zolpidem contain acetamide (Carbonyl group and amine group) as functional groups.
An attempt has been made to determine zolpidem by reacting the secondary amine group
with MBTH reagent. The drug reacts with MBTH in the presence of FeCl3 to give a green
colored product (Scheme 7). This is an iron catalyzed oxidative coupling reaction of MBTH
with the drug. Under the reaction conditions, on oxidation, MBTH loses two electrons and
one proton forming an electrophilic intermediate, which is the active coupling species. This
intermediate undergoes electrophilic substitution with the drug to form green colored product
with absorption maximum of 664 nm. 
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7.2 REACTION INVOLVED 
7.3 
Scheme 7: Reaction of MBTH reagent and ZT
REAGENTS USED
7.3.1 3-Methyl-2-Benzthiazolinone hydrochloride (MBTH) 0.5 %( w/v)
0.5 g of MBTH reagent was accurately weighed transferred into a 100 ml calibrated
flask, dissolved in distilled water, and make up the volume up to the mark to obtain a solution
of 0.5%  ( w/v).
7.3.2 Ferric chloride (1%)
It was prepared by dissolving 1.0 g of ferric chloride in 100 ml of distilled water.
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7.4 PREPARATION OF STANDARD CALIBRATION CURVE 
7.4.1 Preparation of standard stock solution
Accurately weighed 100.0 mg of zolpidem (bulk drug) was dissolved in 40.0 ml of
methanol  in 100 ml volumetric flask and sonicated for about 15 min to enhance the solubility
and volume was made up to the mark with methanol to obtain final concentration of 1.0
mg/ml.
7.4.2 Preparation of calibration curve
Aliquots of zolpidem ranging from 0.5- 3.5 ml (50- 350 µg/ml) were pipette into a
series of 10 ml volumetric flask. To each flask 2 ml of MBTH, 2 ml of ferric chloride was
added and the volume was made up to mark with distilled water and allowed to stand for 20
minutes. The colored species was stable for 2 hours and the amount of drug in the sample was
computed from its calibration curve represented in Fig.13 and Fig. 14.
7.5 ANALYSIS OF CAPSULE DOSAGE FORM
10 tablets (Zolfresh 10 mg) were weighed and their contents were mixed thoroughly.
An accurately weighed portion of powder equivalent to the 100 mg of zolpidem was weighed
into a 100 ml volumetric flask containing about 50 ml of methanol. It was shaken thoroughly
for about 5-10 minutes, filtered through whatman filter paper to remove insoluble matter and
diluted to the mark with methanol to prepare 1000 µg/ml solution. An aliquot of this solution
was diluted with water to obtain a concentration of 100 µg/ml. Then to that solution 2 ml of
MBTH  and  2  ml  of  FeCl3 were  added.  The  mixture  was  then  gently  shaken  and  the
appearance of green color was observed. The contents were diluted up to 10 ml with distilled
water.
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Fig.13. Absorption spectra of
MBTH with ZT against the reagent blank
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           Fig.14. Calibration graph of ZT with MBTH
METHOD 8 (ESTIMATION OF ZOLPIDEM BY 2, 4 – DNP REAGENT)
8.1 PRINCIPLE INVOLVED
 In this method 2, 4-DNP is oxidized by potassium iodate to give diazonium cation
which reacts with drug by electrophilic substitution to give deep colored chromogen (Scheme
8) with absorption maximum of 416 nm.
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8.2 REACTION INVOLVED 
Scheme 8: Reaction of 2,4-DNP and ZT
8.3 REAGENTS USED
8.3.1 2, 4-Dinitrophenyl hydrazine (2, 4-DNP) 0.08 %( w/v)
A 0.08% w/v of the reagent solution was freshly prepared by dissolving 0.08 g of 2, 4-
DNP in 2 ml of concentrated sulphuric acid and diluting to 100 ml with water.
68
8.3.2 10N Sodium hydroxide solution.
40 g of sodium hydroxide was dissolved in 100 ml of distilled water.
8.3.3 Potassium iodate 4 % (w/v)
A 4% w/v potassium iodate solution was prepared by dissolving 4 g in 100 ml of
distilled water.
8.4 PREPARATION OF STANDARD CALIBRATION CURVE 
8.4.1 Preparation of standard stock solution
Accurately weighed 100.0 mg of zolpidem (bulk drug) was dissolved in 40.0 ml of
methanol in 100 ml volumetric flask and sonicated for about 15 min to enhance the solubility
and volume was made up to  the mark with methanol to obtain final concentration of 1000
µg/ml (Stock solution ).
8.4.2 Preparation of calibration curve
Aliquots of zolpidem ranging from 0.2- 0.9 ml (20- 90 µg/ml) were pipette into a
series of  10 ml  volumetric  flask.  To these solutions 1.5  ml of  2,  4-DNP  and 1.5 ml of
potassium iodate
 
were added, which were made alkaline by adding 1 ml each of sodium
hydroxide. The red color hence developed was further diluted to the volume with water. The
amount of drug in the sample was computed from its calibration curve represented in Fig. 15
and Fig. 16.
8.5 ANALYSIS O DOSAGE FORM
10 tablets were weighed and their  contents were mixed thoroughly.  An accurately
weighed portion of  powder equivalent  to the 100 mg of ZT was weighed into a  100 ml
volumetric flask containing about 75 ml of methanol. It was shaken thoroughly for about 5-
10 min, filtered through whatman filter paper to remove insoluble matter and diluted to the
mark with methanol to prepare 1000 µg/ml solution. An aliquot of this solution was taken in a
10 ml volumetric flask to obtain a concentration of 60 µg/ml. Then to that solution 1.5 ml of
2, 4-DNP was added, and 1.5 ml of potassium iodate and 1 ml of 10 N sodium hydroxide
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were added.  The mixture was then  gently shaken until  the appearance of  red color.  The
contents were diluted up to 10 ml with methanol.
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Fig.15. Absorption spectra of 2, 4-DNP with ZT against the reagent blank
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Fig. 16. Calibration graph of ZT with 2, 4-DNP
METHOD 9 (ESTIMATION OF ZOLPIDEM BY p-CA)
9.1 PRINCIPLE INVOLVED
In  this  method  the  interaction  of  zolpidem  with  pi-acceptor  (p-CA)  at  room
temperature was found to yield colored charge transfer complex (Scheme 9) with absorption
maximum of 530 nm. In polar solvents, complete electron transfer from zolpidem (D) as an
electron donor to the acceptor moiety (A) takes place resulting in the formation of intensely
colored radical anions. The reaction sequence can be shown as
                   D +A                                          (D-A)                                    D+ + A-
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   Complex  Radical anions
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9.2 REACTION INVOLVED 
Scheme 9: Reaction of p-CA and ZT
9.3 REAGENTS USED
9.3.1 P-Chloranilic acid (p-CA) 0.2% (w/v)
A 0.2% w/v of the reagent solution was freshly prepared by dissolving 0.2 g of p-CA
in 100 ml of methanol.
9.4 PREPARATION OF STANDARD CALIBRATION CURVE 
9.4.1 Preparation of standard stock solution
Accurately weighed 100.0 mg of zolpidem (bulk drug) was dissolved in 40.0 ml of
methanol in 100 ml volumetric flask and sonicated for about 15min to enhance the solubility
and volume was made up to  the mark with methanol to obtain final concentration of 1000
µg/ml (Stock solution ).
73
9.4.2 Preparation of calibration curve
Aliquots of zolpidem ranging from 0.2- 2.9 ml (20- 290 µg/ml) were pipette into as
series of 10 ml volumetric flask.  To each 1 ml of p-CA reagent was added and the volume
was made up to mark with methanol. The colored product was formed immediately at room
temperature (25±10C) and absorbance was measured after 2 minutes of mixing at 530 nm
against the reagent blank, and the calibration curve and absorption spectra are represented in
Fig. 17 and Fig. 18.
9.5 ANALYSIS OF TABLET DOSAGE FORM
10  tablets  were  weighed  and  their  contents  are  mixed  thoroughly.  An  accurately
weighed portion of  powder equivalent  to the 100 mg of ZT was weighed into a  100 ml
volumetric flask containing about 50 ml of methanol. It was shaken thoroughly for about 5-
10 min, filtered thorough whatman filter paper to remove insoluble matter and diluted to the
mark with methanol to prepare 1000 µg/ml solution. From the above stock solution 0.5 ml
was taken in a 10 ml volumetric flask to obtain a concentration of 50 µg/ml. Then to that
solution  1  ml  of  p-CA reagent  was  added  and  the  volume  was  made  up  to  mark  with
methanol. The colored product was formed immediately at room temperature (25±10C) and
absorbance was measured after 2 minutes.
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Fig.17. Absorption spectra of p-CA with ZT against the reagent blank
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Fig.18. Calibration graph of ZT with p-CA
PART B: GAS CHROMATOGRAPHY METHOD
METHOD 10: (ESTIMATION OF PREGABALIN BY GAS   CHROMATOGRAPHY)
10.1 PRINCIPLE INVOLVED
Pregabalin possesses different functional groups such as carboxylic acid and primary
amine group. Ethylchloroformate acts as derivatizing agent. ECF reacts with primary amine
group  present  in  pregabalin  and  forms  volatile  product  and  eluted  from  a  capillary  GC
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column,  each  having  a  single  peak.  The reaction  was  carried  out  in  methanol.  Aqueous
solution of pyridine is used as a reaction medium for better GC response.
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10.2 REACTION INVOLVED 
                   (a)
                   (b)
              
Scheme 10: Structure of the derivative ECF (a) ECF (b) Dervitized product of PGB with
ECF
10.3 INSTRUMENT:
GC studies were carried out on SHIMADZU model 2014 (Shimadzu Technologies,
Japan) coupled with a  split/split  less  injector  and  FID.  The computer  with  GC solutions
software  has  been  used  to  control  the  gas  chromatograph  attached  with  a  Cannon laser
printer. Rtx-5 capillary column (cross bond 5% diphenyl/ 95% dimethyl polysiloxane) with a
length of 30 meters and an internal diameter of 0.25 mm was used throughout the study.
77
10.4 CHEMICALS AND REAGENTS
Analysis  was  performed  on  methanol  solutions  of  PGB.  All  the  standards,  ECF,
chloroform,  pyridine  were  supplied  by  Sigma  and  met  Pharamcopoeial  requirements.
Methanol of analytical quality was procured from MERK (Worli, Mumbai)
10.5 PREPARATION OF STANDARD STOCK SOLUTION
Pregabalin solution at a concentration of 1mg/ml was prepared and diluted to obtain
serial dilutions from 2 to10 µg/ml. The solutions were kept below 50C and were protected
from light. 
10.6 CHROMATOGRAPHIC CONDITIONS
The GC-FID parameters used in the method development were based on the boiling
point of the drug. The injection port and detector temperature were set to 170˚C and 250˚C,
respectively
Manual splitless injection of approximately 2 µl  sample was performed at an inlet
temperature of 170˚C. The detector temperature was set to 250˚C. After injection, the oven
temperature was increased from 80˚C to 160˚C at a rate of 100˚C per min for 5 min. The
initial pressure of carrier gas (Nitrogen) was maintained at 83.7 Kpa for 3.5 minutes and
pressure was increased at a rate of 20 Kpa/min up to 120 Kpa and held constant for 5 min.
 Synthetic air (flow rate of 100 ml/min), hydrogen (25 ml/min) were fed to the FID.
All the gases used in these studies were of Pharamcopoeial purity. 
PGB  analysis  was  performed  after  derivatization,  PGB  is  a  polar  molecule  and
therefore, a polar solvent methanol was used as the diluent. The capillary column coated with
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5% diphenyl/ 95% dimethyl polysiloxane is a good choice for separation of this analyte since
they elute as symmetrical peaks at a wide range of concentrations.
10.7 ASSAY
Standard solutions of PGB in HPLC grade methanol, having final concentrations in
the range of 2-10 µg/ml were prepared. The drug solution and ECF were added in 1:1 ratio.
The solution was heated at 700 C for 5 minutes. Solution was evaporated after addition of
pyridine and chloroform. Upper layer was collected, redissolved in methanol. 2 µl aliquot of
each  derivatized  sample  solution  was  injected  on  to  the  column  and  the  chromatogram
(Fig.19.) was recorded. Calibration graph was constructed by plotting the mean peak area as a
function of pregabalin concentration (Fig.20.)
10.8 ANALYSIS OF TABLET DOSAGE FORM
Five capsules were weighed and their contents are mixed thoroughly An amount of
powder equivalent to the average weight of a capsule was mixed with methanol and shaken
for 20 min at a frequency of approximately 3 cycle’s/s. The solution was then filtered through
0.2 µm membrane filter  paper.  The drug solution and ECF were added in 1:1 ratio.  The
solution was heated at 700 C for 5 minutes. Solution was evaporated after addition of pyridine
and  chloroform.  Upper layer  was  collected,  redissolved in  methanol.  Chromatogram was
shown in the (Fig.21.)
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Fig.19. Chromatogram obtained from Pregabalin (PGB) solution, Methanol (A), ethyl
chloroformate (B), pregabalin (C)
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      Fig.20. Calibration graph of PGB with ECF
Fig.21. Chromatogram obtained from Pregabalin (PGB) capsule solution. Methanol (A),
ethyl chloroformate (B), pregabalin (C)
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METHOD 11: (ESTIMATION OF ZOLPIDEM BY GAS CHROMATOGRAPHY)
11.1 PRINCIPLE INVOLVED
Zolpidem  contain  acetamide  (keto  group  and  amine  group)  as  functional  group.
Ethylchloroformate  acts  as  derivatizing  agent.  ECF  reacts  with  secondary  amine  group
present in zolpidem and forms volatile product and elutes from a capillary GC column, each
having a single peak. The reaction was carried out in methanol. Aqueous solution of pyridine
was used as a reaction medium for better GC response.
11.2 REACTION INVOLVED 
             (a)
                 (b)              
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Scheme 11: Structure of the derivative ECF (a) ECF (b) Dervitized product of zolpidem
with ECF.
11.3 PREPARATION OF STANDARD STOCK SOLUTION
Zolpidem solution at a concentration of 1mg/ml was prepared and diluted to obtain
serial dilutions from 2 to10 ng/ml. The solutions were kept below 50C and were protected
from light. 
11.4 CHROMATOGRAPHIC CONDITIONS
The GC-FID parameters used in the method development were based on the boiling
point of the drug. The injection port and detector temperature were set to 1700C and 2500C,
respectively. 
Manual splitless injection of approximately 2 µl  sample was performed at an inlet
temperature of 1700C. The detector temperature was set to 2500C. After injection, the oven
temperature was increased from 800C to 1800C at a rate of 1000C per min for 5 min. The
initial  carrier  gas  pressure  (Nitrogen)  was  maintained  at  29.8  Kpa  for  3.5  minutes  and
pressure was increased at a rate of 20 Kpa/min up to 120 Kpa and held constant for 4.50 min.
 Synthetic air (flow rate of 100 ml/min), hydrogen (25 ml/min) were fed to the FID.
All the gases used in these studies were of Pharamcopoeial purity. 
ZT analysis was performed after derivatization, ZT is a polar molecule and therefore,
a  polar  solvent  methanol was used as  the diluent.  The capillary column coated with 5%
diphenyl/ 95% dimethyl polysiloxane is a good choice for separation of this analyte since
they elute as symmetrical peaks at a wide range of concentrations.
11.5 ASSAY
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Standard solutions of ZT in HPLC grade methanol, having final concentrations in the
range of 2-10 µg/ml were prepared. The drug solution and ECF were added in 1:1 ratio. The
solution was heated at 700 C for 5 minutes. Solution was evaporated after addition of pyridine
and chloroform. Upper layer was collected,  redissolved in methanol. 2 µl aliquot of each
derivatized sample solution was injected on to the column and the chromatogram (Fig.22.)
was recorded. Calibration graph was constructed by plotting the mean peak area as a function
of zolpidem concentration (Fig.23.)
11.6 ANALYSIS OF TABLET DOSAGE FORM
10 tablets were weighed and their  contents were mixed thoroughly An amount of
powder equivalent to the average weight of a capsule was mixed with methanol and shaken
for 20 min at a frequency of approximately 3 cycle’s/s. The solution was then filtered through
0.2 µm membrane filter  paper.  The drug solution and ECF were added in 1:1 ratio.  The
solution was heated at 700 C for 5 minutes. Solution was evaporated after addition of 2 ml
pyridine  and  2  ml  chloroform.  Upper  layer  was  collected,  redissolved  in  methanol.
Chromatogram is shown in the Fig.24.
Fig.22. Chromatogram obtained from Zolpidem (ZT) solution, Methanol (A), ethyl
chloroformate (B), zolpidem (C)
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Fig.23. Calibration graph of Zolpidem
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RESULTS AND DISCUSSION
PART A: UV/VISIBLE SPECTROMETRIC METODS
Table 1: Optical characters of pregabalin spectrophotometric methods
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S.
N
O
      
Paramete
r
         NQS            
Sange
rs
        
MBTH
          
Gibb’s
 
          
BMR
         
2,4-
DNP
1.
λmax/ nm 485 nm 353
nm
668 nm 400 nm 471nm 461 nm
2. Beers law
limits
(µg/ml)
5-45 5-13 50-350 50-350 50-350 50-450
3. Molar
absorptivit
y(liter
/mol/cm)
0.17834x1
0-02
0.741x
10-02
4.202 ×10-4 3.693x10-4 8.862x10-4 0.27382
4×10-3
4. Correlatio
n
coefficient
(R)
0.993 0.995 0.998 0.999 0.999 0.998
5. Sandell’s
sensitivity
(g/ml
0.001 abs
unit)
0.0546 0.0892 0.378 0.4310 0.862 0.212
6. Regressio
n equation
(Y)
Y=0.018x
+0.008
Y=0.0
57x-
0.013
Y=0.0025x
+0.0096
Y=0.0021x
+0.005
Y=0.0021
x+0.05
Y=0.00
1x-
0.007
7. Slope, b 0.018 0.057 0.002 0.002 0.001 0.001
8. Intercept,
a
0.008 0.013 0.0096 0.005 0.003 0.007
     
   
9.
µ Relative
standard
deviation
0.487 0.804 0.35 0.36 0.38 0.25
              Table 2: Validation parameters of pregabalin spectrophotometric methods
        
    
S.N
O
      Parameter          
NQS
          
Sangers
        
MBT
H
          
Gibb’s
 
          
BMR
         2,4-
DNP
1 Limit of detection
(%g/ml)
0.29 0.24 2.45 2.45 3.99 1.90
2 Limit of
quantification(µg/ml
)
0.88 0.74 7.44 7.17 12.11 5.77
3 % Intraday RSD 0.238 0.2137 0.32 0.38 0.40 0.25
4 % Interday RSD 0.487 0.804 0.5 0.78 0.73 0.59
5 Standard error of
mean
0.015
2
0.0035 0.0013 0.0018 0.0004 0.0042
                                       
Table 3: Recovery studies of pregabalin spectrophotometric methods
Formulatio
n
Metho
d
Level of 
% 
Recover
y
Sampl
e PGB
µg/ml
Standar
d PGB 
µg/ml
Avg 
amount 
from 
calibratio
n graph
Avg 
%Recover
ya
% 
RS
D
     Pregeb 
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NQS
80% 10 12 21.96 99.53 0.13
100% 10 15 24.98 99.71 0.16
120% 10 18 27.97 99.72 0.13
Sangers 80% 5 4.8 9.78 99.54 0.10
100% 5 6.0 10.98 99.62 0.14
120% 5 7.2 12.18 99.59 0.16
MBTH 80% 50 80 129.5 99.54 0.20
100% 50 100 149.8 99.66 0.15
120% 50 120 169.83 99.85 0.22
Gibbs 80% 50 80 129.6 99.37 0.15
100% 50 100 149.7 99.43 0.25
120% 50 120 169.6 99.65 0.16
BMR 80% 50 80 129.4 99.48 0.23
100% 50 100 149.6 99.55 0.29
120% 50 120 169.3 99.36 0.19
2,4- DNP 80% 50 80 129.8 99.75 0.22
100% 50 100 149.5 99.30 0.20
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120% 50 120 169.8 99.63 0.15
a = average of three determinations
                        Table 4: Optical characters of Zolpidem spectrophotometric methods
S.NO                Parameter                     MBTH                  2,4 
DNP
                 p-
CA
     1
λmax (nm) 664 nm 416 nm 530 nm
2 Beers law limits
(µg/ml)
50-350 20-90 20-290
3 Molar absorptivity
(liter /mol/cm)
2.1386 ×10-3 6.5781×10-3 1.530×10-3
4 Correlation
coefficient (R)
0.998 0.998 0.999
5 Sandell’s sensitivity
(µg/ml 0.001 abs
unit)
0.378 0.1162 0.50
6 Regression equation
(Y)
Y=0.002x+0.011 Y=0.09x-0.005 Y = 0.002x-
0.001
7 Slope, b 0.002 0.090 0.002
8 Intercept, a 0.011 0.005 0.001
    9
µ Relative standard
deviation
0.20 0.41 0.33
Y= bC+a, where C is the concentration of Zolpidem in µg/ml and Y is the absorbance at the
respective maximum absorbance
Table 5: Validation parameters of zolpidem spectrophotometric methods
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S.NO Parameters            MBTH           2,4 DNP               p-CA
1 Limit of detection (%g/ml) 3.085 0.836 1.914
2 Limit of
quantification(µg/ml)
9.35 2.53 5.80
3 % Intraday RSD 0.50 0.66 0.36
4 % Interday RSD 0.62 0.78 0.54
5 Standard error of  mean 0.000477 0.000930 0.000763
                         Table 6: Recovery studies of Zolpidem spectrophotometric methods
PART B: GAS CHROTOGRAPHIC METHOD
Table 7: Validation parameters of Pregabalin and Zolpidem Gas chromatographic
methods
S.NO
                 
             Parameters
                          
Pregabalin
                    
            Zolpidem 
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Formulatio
n
Metho
d
Level of 
% 
Recover
y
Sampl
e ZT 
µg/ml
Standar
d ZT 
µg/ml
Avg 
amount 
from 
calibratio
n graph
Avg 
%Recover
ya
% 
RS
D
Zolfresh
MBTH
80% 50 80 129.3 99.37 0.24
100% 50 100 149.4 99.56 0.21
120% 50 120 169.2 99.43 0.14
2,4- DNP
80% 20 24 43.82 99.44 0.18
100% 20 30 49.80 99.36 0.27
120% 20 36 55.83 99.48 0.16
p-CA
80% 20 40 59.80 99.53 0.21
100% 20 50 69.60 99.46 0.25
120% 20 60 79.90 99.63 0.15
1 Linearity 2-10 µg/ml 2-10 ng/ml
2 Limit of detection 5.295 x 10-5 0.0116 
3 Limit of quantification 1.605 x 10-4 0.0350
5 % Intraday RSD 0.0066 0.023
6 % Interday RSD 0.0167 0.250
7 Relative retention time (min) 0.994 1.0075
                                                
 Table 8: Recovery studies of Pregabalin gas chromatography method
                                                                                                         
                                                             a: average of six replicate determination
                          Table 9: Recovery studies of Zolpidem gas chromatography method
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Drug Level of 
% 
Recovery
Sample 
PGB      
µg/ml
Standard 
PGB µg
Avg amount 
from 
calibration 
graph
Avg 
%Recovery
a
% 
RSD
 
Pregabali
n
80% 2 3.2 5.20 100.06 0.042
100% 2 4 5.99 99.74 0.035
120% 2 4.8 6.80 100.04 0.045
 Drug Level of 
% 
Recovery
Sample 
ZT         
ng/ml
Standard ZT 
ng/ml
Avg amount 
from 
calibration 
graph
Avg % 
Recovery
a
% 
RSD
 
Zolpide
m
80% 2 3.2 5.199 99.90 0.056
100% 2 4 5.996 99.95 0.042
120% 2 4.8 6.80 100.13 0.030
                      
a: average of six replicate determination
DISCUSSION
PART A: UV- VISIBLE SPECTROPHOTOMETRY
The  optical  characteristics  such  as  absorption  maxima,  Beer’s  law  limits,  molar
absorptivity,  saddle’s sensitivity are given in the  Table 1 and  Table 4 for pregabalin and
zolpidem respectively. The regression analysis using the least squares was made for the slope
(b) intercept (a) and correlation (R) obtained from different concentrations and results are
summarized in table 1 and table 4. The percentage relative standard deviation calculated from
the six measurements and summarized in Table 1 and Table 4. The results showed that the
methods have reasonable precision. 
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Results obtained with the proposed methods confirm the suitability of these methods
for pharmaceutical dosage forms. The other active ingredients and excipients usually present
in the pharmaceutical dosage forms did not interfere in the estimation when some commercial
dosage forms were analyzed by these methods. The accuracy of the method is confirmed by
the recovery studies, by adding known amount of the pure drug to the formulation already
analyzed  by  this  method  and  the  analytical  data  presented  in  Table  3 and  Table  6 for
pregabalin and zolpidem respectively.
In all the above methods, the optimum concentration for the estimation of pregabalin
and zolpidem was established by varying one parameter at a time and keeping the other fixed
and observing the effect of product on the absorbance of the colored species and incorporated
in the procedures.  The optimum concentration of pregabalin and zolpidem established by
varying drug concentration and by keeping the reagent concentration fixed. After establishing
the optimum concentration for drug, the reagent concentration was varied. The above ranges
of drug and reagents concentrations were chosen because the colored species formed gave
better absorbance and obeyed beer’s law satisfactorily.
The methods reported here are found to be simple, sensitive, accurate, precise and
economical  and  can  be  used  in  the  determination  of  pregabalin  and  zolpidem  from
pharmaceutical dosage forms in a routine manner.
PART B: GAS CHROMATOGRAPHY
The development  of  analytical  method for  the determination of  drugs  by GC has
received considerable attention in recent years because of their importance in quality control
of drugs and drug products. The objective of this study was to develop a rapid and sensitive
GC method for the analysis of pregabalin and zolpidem in bulk and its formulation using the
most commonly employed Rtx-5 capillary column with FID detection.
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 The  run  time  was  set  at  10.53  min  and  10.83  for  pregabalin  and  zolpidem
respectively. Pregabalin appeared on the chromatogram at 7.56 min and zolpidem at 8.003
min. When the samples were injected six times, the retention times of the drugs were same.
The validated parameters such as linearity, LOD, LOQ, recovery, intra and inter day R.S.D
are summarized in Table 7. The peak areas of drugs were reproducible as indicated by low
coefficient of variance. When the concentration of pregabalin and zolpidem and its respective
peak areas were subjected to regression analysis by least squares method, a high correlation
coefficient were observed (r2=0.986 for PGB and r2=0.998 for ZT) in the range of 2- 10 μg/ml
and 2-10 ng/ml for PGB and ZT respectively. The regression equation was used to estimate
the amount of pregabalin and zolpidem in formulations or in validation study (precision and
accuracy).
The proposed  GC methods were  also validated for  intra  and inter  day variations.
Thus, the results showed that the proposed GC method is highly reproducible. When a known
concentration  of  drug solution  was  added  to  preanalyzed  samples  of  commercial  dosage
forms of pregabalin and zolpidem, there was high recovery of these drugs indicating that the
proposed method is highly accurate and the values were presented in Table 8 and 9.
The GC method developed in the present study has been used to quantify pregabalin
and zolpidem in capsule and tablet dosage form respectively. No interfering peaks were found
in the chromatogram indicating that the excipients used in the formulation did not interfere
with the estimation of the drug by the proposed GC method.
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SUMMARY
Several  drugs are available in  the form of  pharmaceutical  formulations  to  control
diseases.  Methods  of  assay  for  controlling  the  concentration  of  these  chemicals  in  the
medicine and in the living body are necessary. Pharmaceutical analysis occupies a pivotal
role in statutory certification of drugs and their formulations either by the industry or by the
regulatory authorities. The complexity of the problem encountered in pharmaceutical analysis
coupled with importance of achieving the selectivity, speed, cost, simplicity, precision and
accuracy  results  in  new  methods  of  analysis  being  quickly  adopted  by  pharmaceutical
industry.
The  ever  increasing  use  of  pharmacodynamics  and  chemotherapeutic  agents  in
pharmaceutical preparations makes their determinations a matter of foremost importance. In
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some cases, no precise analytical methods are reported and quite often the reported methods
need improvement or changes keeping in view of the advances.
Now a day’s  many of the new formulations are rushing into the market.  In  some
cases, no precise analytical methods are reported and quite often the reported procedures need
improvements or changes keeping in the view of the advances.
Among  several  instrumental  techniques  (HPLC,  GC,  fluorimetry,  NMR,  mass
spectroscopy covering  IR,  UV and  visible  regions)  available  for  assay  of  drugs,  visible
spectrophotometric methods depend only on the nature of chemical reaction utilized for color
development and not on sophistication of the equipment. GC method is highly selective and
sensitive compared to spectroscopic or other chromatographic methods. GC method is also
cost effective as expensive solvents are not required and it is a versatile tool for qualitative
and quantitative analysis of drugs and pharmaceuticals.
Due to the importance of analysis, present analytical method has been developed for
some of  the  widely used  drugs  such  as  pregabalin  and  zolpidem.  Hence  we  planned  to
develop both GC and spectrophotometric methods.
There is a wide scope for the development of new analytical methods for the assay of
the pregabalin and zolpidem. Visible spectrometry (part A) and GC (part B) techniques have
been used as a tool in the present thesis work. The above two tools have been used for the
development of new analytical methods for the assay of drugs mentioned by exploiting their
physical and chemical properties (dependent on basic moieties and functional groups present
in each drug).
The  contents  of  the  thesis  have  been  divided  into  eight  chapters  and  appropriate
reference have been placed at the end of the eighth chapter (i.e., ninth chapter) 
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Chapter-1 opens with the introduction giving a brief account of various aspects like
chemotherapy,  instrumental  methods,  concepts  of spectroscopy,  various reagents,  types  of
chromatographic methods,  general  analytical  method development  and method validation.
The introduction includes brief account on selected drugs.
Chapter- 2 explains the objective of present investigation adopted for selected drug.
Chapter-3 for review of literature gives details on reported methods, clinical studies
under  different  experimental  conditions,  drug  introduction  and  therapeutic  importance  of
selected drug for present work. Also it gives information about the necessity to investigate
new analytical methods for pregabalin and zolpidem for the quantitative estimation.
Chapter-4  contains  two  parts  i.e.  part  A and  part  B.   Part  A gives  information
regarding  visible  spectrophotometric  method  (1  -  9).  It  briefly  explains  about  principle
involved  in  the  method,  proposed  reaction,  reagents  and  materials  used,  preparation  of
standard solutions, preparation of calibration curve, analysis of capsule dosage form. Primary
amine  group  in  pregabalin  and  amide  group  in  zolpidem  was  exploited  in  the  present
investigations for the development of the methods.
In method 1 primary amine group of pregabalin reacts with NQS reagent in alkaline
medium  at  room  temperature.  The  reaction  followed  the  formation  of  orange  colored
chromogen  exhibiting  the  absorption  maximum  at  485  nm  and  obeys  beers  law  in  the
concentration range 5-45 μg/ml.
In method 2 primary amine group of pregabalin reacts with Sanger reagent in alkaline
medium (buffer pH 9).  The reaction results in a yellow coloured complex with absorption
maximum at 353 nm. Beer’s law is obeyed in the concentration range of 5-13 μg/ml.
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In method 3 primary amine group of pregabalin reacts with MBTH reagent in the
presence of ferric chloride and forms a green colored product with absorption maximum at
668  nm. Beer’s law is obeyed in the concentration range of 50-350 μg/ml.
In method 4 primary amine group of pregabalin reacts with Gibbs reagent. In  this
method oxidation of the drug with the reagent takes place and forms brown colored product
with absorption maximum at 400 nm. Beer’s law is obeyed in the concentration range of 50-
350 μg/ml.
In method 5 primary amine group of pregabalin reacts with BM reagent. This reaction
depends on diazotization of drugs with nitrous acid, to form nitrous acid, to form diazotized
compound, followed by its coupling with N-(1-naphthyl) ethylene- diamine dihydrochloride
[Bratton-Marshall reagent] to form a violet colored chromogen with absorption maximum of
471 nm. Beer’s law is obeyed in the concentration range of 50-350 μg/ml.
In  method 6  carboxylic  group  of  pregabalin  reacts  with  2,4-DNP reagent. In  this
reaction 2, 4-DNP is oxidized by potassium iodate to give diazonium cation which reacts with
drug by electrophilic substitution to give deep colored chromogen with absorption maximum
of 461 nm. Beer’s law is obeyed in the concentration range of 50-450 μg/ml.
In method 7 amide group of zolpidem reacts with MBTH reagent in the presence of
ferric  chloride and forms a green  colored  product  with  absorption maximum at  664 nm.
Beer’s law is obeyed in the concentration range of 50-350 μg/ml.
In method 8 keto group of zolpidem reacts with 2,4DNP reagent. In this reaction 2, 4-
DNP is oxidized by potassium iodate to give diazonium cation which reacts with drug by
electrophilic substitution to give deep colored chromogen with absorption maximum of 461
nm. Beer’s law is obeyed in the concentration range of 20-90 μg/ml.
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In method 9 amide group of zolpidem reacts with parachloranilic acid (p-CA) at room
temperature. p-CA act as a pi-acceptor and undergo electron transfer and forms colored charge
transfer  complex  with  absorption  maximum  of  530  nm.  Beer’s  law  is  obeyed  in  the
concentration range of 20-290 μg/ml.
Part  B  describes  about  the  gas  chromatographic  method  (10  and  11).  It  gives
information regarding the principle involved in the gas chromatography developed by using
derivitizing  agent,  proposed  reaction,  instrument,  chemicals,  reagents,  chromatographic
conditions, assay and analysis of commercial formulation. Ethylchloroformate is used as a
deravitizing agent  and reacts  with  primary amine  and secondary amine  group  present  in
pregabalin and zolpidem respectively. This reaction makes the compounds more volatile and
helps in the elution of peaks with better resolution. Rectilinear relationship was observed
between 2-10 μg/ml and 2-10 ng/ml for pregabalin and zolpidem respectively.
Chapter 5 explains the results that are divided into two parts part A and part B. In
part A, results obtained in each of the UV-Visible spectrophotometric method for estimation
of pregabalin and zolpidem are summarized in Tables 1-6. In part B, the results obtained for
the gas chromatography determination of pregabalin and zolpidem are summarized in Table
7-9.
Chapter 6  consists of discussion which is divided into two parts. Part A discusses
about developed visible spectrophotometric methods. Part B discusses about developed GC
method.
Chapter  7 explains  the  conclusion  of  the  proposed  methods  for  the  quantitative
estimation of pregabalin and zolpidem. A set of eleven methods has been developed for the
purpose and these methods are validated in terms of sensitivity, accuracy and precision.
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These  methods  can  also  be  used  for  the  routine  determination  of  pregabalin  and
zolpidem in bulk drug and pharmaceutical formulations.
Chapter 9  contains  the  references  from which  the  information  of  pregabalin  and
zolpidem and introduction of general methodology was collected.
Chapter 10 contains the list of paper communicated so far to various journals.
CONCLUSION
PREGABALIN
Pregabalin is  an anticonvulsant drug  used  for neuropathic  pain and  as  an  adjunct
therapy for partial  seizures with or  without  secondary generalization in  adults.  Chemically
pregabalin  is  [S-[+]-3-isobutyl  GABA or  (S)-3-(amino  methyl)-5-methylhexanoic  acid. It
binds with high affinity to the alpha2-delta site (an auxiliary subunit of voltage-gated calcium
channels) in central nervous system tissues. The drug is available in capsule dosage form. 
 In previous reports high performance liquid chromatographic methods and only few
spectrophotometric  methods  were  developed.  Need  for  the  development  of  simple
spectrophotometric methods for its assay is highly demanding. In the view of above fact,
some simple analytical methods were planned to develop with sensitivity, accuracy, precision
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and economical. Since pregabalin is soluble in distilled water and methanol, a number of
spectrophotometric methods can be developed for the quantitative estimation of drug in bulk
and pharmaceutical formulations.
In part A set of six simple, sensitive, accurate and precise spectrophotometric methods
(methods 1 to 6) has been developed for the purpose. The results expressed in Table 1-3 for
spectrophotometric methods. The striking advantage of all the presently developed methods
is that they are economical.
The methods are validated in terms of sensitivity, accuracy and precision.
A. Comparative Sensitivity:
                1 > 2 > 6 > 3 > 4> 5
B. Comparative accuracy:
                3> 2 >1 > 4 > 5 > 6
C. Comparative precision:
    6 > 3 > 4 > 5 > 1 > 2
These methods can be used for the routine determination of pregabalin in bulk drugs
and in pharmaceutical formulations.
In part B, in present investigation, we have developed sensitive, precise and accurate
gas chromatography method (method 10) for the quantitative estimation of pregabalin in its
bulk  and  pharmaceutical  formulations.  The  results  expressed  in  Table  7  and  8  for  gas
chromatography is  promising.  The  advantage  of  the  developed  GC  method  is  that  it  is
sensitive and precise. As only small quantity of solvents is used the method is proved to be
economical. 
This method can be used for the routine determination of pregabalin in bulk drugs and
pharmaceutical formulations.
ZOLPIDEM
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Zolpidem is a prescription medication used for the short-term treatment of insomnia,  as
well as some brain disorders. Chemically zolpidem is  N, N, 6-trimethyl-2-p-tolyl-imidazole
(1,2-a)  pyridine-3-acetamide  L-(+)-tartrate.  It  is  a  short-acting
nonbenzodiazepine hypnotic that  potentiates gammaaminobutyric  acid (GABA),  an
inhibitory neurotransmitter,  by  binding  to GABAA  receptors at  the  same  location
as benzodiazepines. The drug is available in tablet dosage form.
It  is  official  in  British Pharmacopoeia.  A HPLC method has been reported in  the
British pharmacopoeia. Need for the development of simple spectrophotometric methods for
its assay is highly demanding.
Here  three  simple  sensitive  precise  and  accurate  UV-visible  spectrophotometric
methods have been established for the quantitative estimation of zolpidem in its bulk and
pharmaceutical formulations. The results are given in Table 4-6. The methods are validated in
terms of sensitivity, accuracy and precision.
A. Comparative Sensitivity
         2 > 1 > 3
B. Comparative accuracy:
        3 >1 > 2  
C. Comparative precision:
    1 > 3 > 2
These methods can be used for the routine determination of pregabalin in bulk drugs and in
pharmaceutical formulations.
In part B, in present investigation, we have developed sensitive, precise and accurate
Gas  chromatography  method  (method  11)  has  been  established  for  the  quantitative
estimation of pregabalin in its bulk and pharmaceutical formulations. The results expressed in
Table 7  and  9  for gas chromatography is promising. The advantage of this developed GC
method is, it is sensitive.
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